Pharmaco-psychiatry and gut microbiome: A systematic review of effects of psychotropic drugs for bipolar disorder

Truong An Bui[1], Benjamin R. O'Croinin[2], Liz Dennett[3], Ian R. Winship[1], Andrew Greenshaw[1#]

[1] Neurochemical Research Unit, Department of Psychiatry, Faculty of Medicine and Dentistry, Edmonton, AB, Canada
[2] Faculty of Medicine and Dentistry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
[3] Geoffrey and Robyn Sperber Health Sciences Library, University of Alberta, Edmonton AB, Canada
Corresponding author: Andrew Greenshaw (Email: ajgreenshaw@gmail.com)

Keywords: bipolar disorder, gastrointestinal microbiota/microbiome, mood stabilizers, antipsychotics

Short title: Psychotropic drugs and gut microbiome in bipolar disorder

Abstract

Despite being one of the most common and debilitating mood disorders, bipolar disorder is often misdiagnosed and undertreated. Its pathogenesis is complex, with significant patient variability and inconsistent treatment effectiveness. The brain-gut-microbiota axis plays a critical role in bipolar disorder by modulating neurotransmitter secretion, gut peptides, and systemic inflammation. However, the mechanisms by which psychotropic treatments influence gut microbiota composition and their implications for clinical outcomes remain poorly understood. This systematic review evaluated the impact of psychotropic drugs on gut microbiota and their potential role in bipolar disorder treatment outcomes.

A comprehensive search across Ovid MEDLINE, Embase, APA PsycINFO, Scopus, and PubMed yielded 314 articles, of which 12 met the inclusion criteria (last search: 13 August 2024). The studies included were those on adults with bipolar disorder type I or II receiving psychopharmacological treatments, those with group comparisons (e.g., medicated vs. non-medicated) investigating gut microbiome changes; no restrictions applied to psychotic features, comorbid anxiety, or prior treatment responses. Exclusions involved individual case reports, incomplete conference submissions, or early terminated studies lacking efficacy analysis. Cochrane ROBINS-I V2 tool was used to measure the risk of bias, and the GRADE approach was utilized to rate the certainty of evidence in included studies. Two authors independently extracted data into Excel spreadsheets, categorizing demographic and clinical characteristics, describing microbiome analytic methods, and summarizing findings on gut microbiome changes post-treatment. Given the high variability in methods and outcome measures across studies, all details were reported without data conversion.

Data synthesis reveals that psychotropic treatments, including quetiapine and lithium, influence gut microbiota by increasing the abundance of beneficial bacteria supporting gut health and pathogenic bacteria linked to metabolic dysfunction. Notably, female patients exhibited more significant changes in microbial diversity following psychotropic treatment. Additionally, patients treated with psychotropics showed an increased prevalence of gut bacteria associated with multidrug antibiotic resistance. In bipolar patients treated with quetiapine, responders—those experiencing improved depressive symptom scores—displayed distinct gut microbiome profiles more closely resembling those of healthy individuals compared to non-responders. Responders also exhibited neural connectivity patterns similar to healthy subjects. These findings underscore the complex dual impact of psychotropic medications on gut microbiota, with potential consequences for both gut and mental health. While the enrichment of beneficial bacteria may support gut health, the rise in antibiotic-resistant and metabolically disruptive bacteria is concerning.

Study limitations include methodological heterogeneity, a high risk of bias in some studies due to incomplete statistical analyses or insufficient control for confounding factors, and potential duplication of study populations arising from overlapping authorship. Further research is essential to elucidate the functional consequences of these microbial shifts and their influence on treatment efficacy. Nevertheless, this review highlights the potential of utilizing gut microbiota profiles to inform personalized treatment strategies, optimize therapeutic outcomes, and minimize side effects in bipolar disorder.

List of figures and tables

Fig 1. Study selection with PRISMA flow diagram.

Fig 2. Risk of bias assessment.

Fig 3. Proposed effects of environmental factors on the gut microbiome composition and neurochemical signalling in bipolar disorder.

Table 1. Studies included for systematic review.

Table 2. Demographic and clinical characteristics of included studies.

Table 3. Study criteria and analysis methodology of included studies.

Table 4. Changes in gut microbiome composition upon psychotropics treatment.

S1 Table. Search strategies by database.

S2 Table. Certainty of evidence assessment.

S3 Table. PRISMA 2020 abstract checklist.

S4 Table. PRISMA 2020 checklist.

Introduction

Gut-brain axis crosstalk and mental illness: an overview

Current interest in a holistic view of nervous system function, including internal and external environmental modulators, now includes the bidirectional crosstalk between the gut and the brain, which is now referred to as the gut-brain axis. This review focuses on the relevance of the gut-brain axis to understanding mechanisms underlying mental illness, with a specific focus on the effects of drugs used to treat bipolar disorder (BP), a prominent and disabling mood disorder.

The gastrointestinal tract contains the largest, most abundant and diverse microbial reservoir in the human body, which serves as the first line of immune defence (1–3). Gut microbiota comprises four major bacteria: *Bacteroidetes*, *Firmicutes*, *Proteobacteria*, and *Actinobacteria* (4–6). This microbiome can modulate the hypothalamic-pituitary-adrenal (HPA) axis, which mediates neuroendocrine and autonomic functions (7,8). With digestion, the gut microbiome produces an abundance of neuroactive metabolites such as neurotransmitters and their precursors, including glutamate, noradrenaline, serotonin (5-HT), dopamine (DA), and gamma-aminobutyric acid (GABA), tyramine, phenylethylamine, and tryptamine that can regulate brain functions and behaviour (9,10). These neurotransmitters play crucial roles in neurological and immunological activities in the brain (11). Disturbed intestinal microbiota, often associated with reduced bacterial diversity, is associated with a variety of psychiatric diseases, including major depressive disorder (MDD) (12–14), BP (15), and schizophrenia (SCZ) (16). Gut microbiome composition is especially sensitive to stressors in the central nervous system (CNS) that can activate the sympathetic nervous system and HPA axis, such as aging, infection, and injuries (17,18). Stress and depression are known to increase gut barrier permeability and cause epithelial barrier defects, or “leaky gut,” which results in gut bacteria, such as *E. coli* and their lipopolysaccharide, translocating into circulatory fluids within the body and evoking an inflammatory response (15,19,20). These can further promote the occurrence and progression of psychiatric disorders (21,22). However, mechanisms for these relationships have yet to be identified (23)

Bipolar disorder epidemiology and pathophysiology

BP is the 17th leading contributor to the global burden of disease, just after MDD, anxiety disorders, SCZ, and dysthymia, affecting >1% of the worldwide population (24,25). In 2019, BP was reported to account for 8.5 million global disability-adjusted life-years (DALYs) (26). The global

economic burdens and healthcare costs of BP are enormous, as they affect not only the patients but also family members and caregivers (27–29).

BP is characterized by biphasic mood episodes of mania (or hypomania) and depression, which result in extreme and unpredictable emotion, thought, and energy disturbances (30,31). Mania can manifest as hyperactivity, irritability, grandiosity, decreased need for sleep, increased talkativeness, distractibility, delusions, flight of ideas, psychomotor agitation, risk-taking behaviour, and highly elevated mood (32,33). In contrast, depressive episodes are characterized by sadness, reduced interest or pleasure, fatigue, social withdrawal, low self-esteem, psychomotor retardation or agitation, sadness, insomnia or hypersomnia, and change in appetite and weight (33,34). Diagnoses of BP in the Diagnostic and Statistical Manual of Mental Disorders (DSM-V-TR) include bipolar I disorder (BP-I), bipolar II disorder (BP-II), cyclothymic disorder, and substance/medication-induced BP (35).

Medications are generally the most critical component of BP treatment (36,37). Pharmacological therapies used for BP can be divided into mood stabilizers, antipsychotics, and anticonvulsants (also known as antiepileptics) (38,39). During acute treatment, a mood state (e.g., depression) may transition or spill over to its opposite (e.g., mania), adding complexity to clinical decisions regarding psychotropic selection and dosing (40–42). This mood switch process is a distinctive feature of BP compared to other psychiatric conditions, presenting a unique challenge in its management (43). Additionally, among patients receiving pharmacotherapy, up to 35% relapse within the first year in adults, and the risk of relapse rises to 65% after 4-5 years (36,37,44,45).

Functional imaging, such as functional magnetic resonance imaging (fMRI) and positron emission tomography (PET), offer a powerful means of investigating the interplay between the gut microbiome and brain activity in BP. Imaging can identify biomarkers that differentiate BP from other psychiatric conditions, such as unipolar depression or SCZ, which often present overlapping symptoms (46). It also allows researchers to assess the impact of pharmacological treatments (e.g., mood stabilizers) and psychotherapy on brain function, providing insights into therapeutic mechanisms, predicting treatment outcomes response, and creating tailored interventions (47–49).

Techniques like PET enable the study of neurotransmitter systems, such as DA and 5-HT, which are implicated in the pathophysiology of BP (50–52). fMRI can identify abnormal connectivity in brain networks like the default mode network (DMN), prefrontal cortex (PFC), hippocampus, and amygdala. These networks govern self-referential thinking and emotional processing and are disrupted in BP (53–56). For example, compared to healthy controls (HC), BP patients have greater functional connectivity (FC) between the salience and DMN (57) and altered activation within the DMN (53,55,58).

5-HT is a pivotal neurotransmitter in mood stabilization, and its dysregulation plays a significant role in the manic and depressive symptoms of BP (59–61). Dysregulation of 5-HT metabolism has been associated with intestinal microbiota-induced inflammation (62–65) and these neurotransmitter abnormalities can be detected through functional imaging techniques such as fMRI and PET (66–68). Previous studies showed that gut dysbiosis can divert tryptophan, the precursor for 5-HT synthesis, into the kynurenine pathway, thereby reducing 5-HT availability while increasing neurotoxic metabolites (69–71). Additionally, short-chain fatty acids (SCFAs) produced by gut bacteria can affect the serotonin transporter expression and 5-HT receptor sensitivity, which regulates 5-HT reuptake (72). Functional imaging can track changes in glucose metabolism in brain regions affected by gut-derived metabolites, offering a direct visualization of how gut health shapes brain energy utilization (73,74).

Psychotropic agents used to treat BP patients are known to induce weight gain and other metabolic disorders such as obesity, insulin resistance, dyslipidemia, hypertension, impaired glucose tolerance, and high rates of atherosclerotic disease (75–84). These side effects suggest a connection between BP pathophysiology/treatment and metabolism, as well as the gut microbiome. Thus, a comprehensive understanding of the interactions between the gut microbiome, pharmacotherapy, and treatment outcomes is vital. Although the relationship between BP and the gut microbiome is still relatively unexplored, available evidence describing differences in gut microbiome composition between BP and HC has been summarized fairly recently (85–88). To our knowledge, this is the first systematic review of the potential effects of psychotropics on the microbiome of treated and untreated BP individuals.

Objectives

As the first systematic review on the topic, this review investigates how pharmacological treatments might modulate inflammatory processes, metabolic functions, and neurotransmitter signalling pathways within the gut-brain axis in BP. Gut microbiome in psychiatric disorders is a very complex and rapidly evolving field, and BP is a heterogeneous disorder, with individuals often experiencing varying responses to pharmacological treatments. BP patients also frequently develop comorbidities, including metabolic syndrome, gastrointestinal issues, and other psychiatric conditions. Exploring the role of the gut-brain axis in the context of BP pharmacotherapy provides a novel lens through which these discrepancies and complexities might be explained and lead to more holistic approaches to managing BP. Moreover, understanding these connections could also pave the

way for novel personalized therapeutic strategies, inspiring further studies and clinical trials focused on microbiome-targeted interventions.

Material and Methods

Inclusion criteria

This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and the PRISMA 2020 checklist was used (89). The PRISMA 2020 checklist and abstract checklist are available in **S3** and **S4 Table**. The inclusion criteria for studies were as follows: (1) studies of adults diagnosed with BP-I or BP-II; (2) participants received psychopharmacological BP intervention (e.g., mood stabilizers, antipsychotics, antidepressants); (3) studies must have group comparisons, such as medicated participants versus placebo/healthy controls/unmedicated participants; (4) studies must investigate the changes in the gut microbiome. There were no limitations regarding the existence of psychotic features, the presence of comorbid anxiety symptoms or disorders, or inadequate responses to prior treatments.

The exclusion criteria were as follows: (1) individual case reports relating to medications; (2) conference submissions that lack complete quantitative or qualitative reports; (3) studies that terminated early without efficacy analysis.

Data collection and search strategy

Strategies to identify eligible studies included a systematic search of five electronic databases: Ovid MEDLINE, EMBASE (via Ovid), APA PsycINFO (via Ovid), PubMed and SCOPUS, up to 13 August 2024. The search was conducted with assistance from a library and information science specialist (LD) to ensure the inclusion of all relevant articles. The search included three concepts combined with boolean AND: bipolar disorder, gut microbiome, and mood stabilizing drugs. Each concept included subject headings and synonyms combined with Boolean OR and was optimized to run in each database. No methodological, publication, language or date limits were added to the search. The full search strategy is available in **S1 Table**.

All citations were reviewed by title, then by abstract, then by full text and were screened according to the inclusion and exclusion criteria by two reviewers independently (TAB and BRO) using the Covidence tool (194). When there was uncertainty regarding the inclusion of an article or disagreement, the final decision was made by AG. A total of 12 full-text articles were selected (**Fig 1**).

Data extraction

Two authors (TAB and BRO) systematically extracted the following information from the included articles into an Excel spreadsheet. Data were extracted in the following categories: (1) demographic and clinical characteristics of the study samples, including sample size, age range, sex ratios, BMI, diagnostic group, medications, inclusion criteria, and exclusion criteria; (2) microbiome analytic methodology includes gut genetic quantification, gut diversity measures, brain imaging (in selected studies), and covariates' effects; (3) study findings, including group differences in taxonomic abundance and correlations between medications and associated gut microbiome characteristic changes. The primary outcomes from these studies were response to treatment and all-cause discontinuation (e.g., withdrawal consent). Since the methods and outcome measures in each study vary greatly from one another, we reported these differences and all details and did not have to do any data conversion.

Risk of bias and certainty of evidence assessment

Given the diverse study designs in our systematic review, risk of bias in included studies was evaluated using the Cochrane risk of bias ROBINS-I V2 tool, which is suitable for cross-sectional interventional and longitudinal interventional studies (90). Two reviewers (TAB and BRO) independently assessed the studies for potential biases, including selection and reporting biases, and resolved discrepancies through discussion (**Fig 2**).

The certainty of the evidence was assessed using the GRADE approach. This method evaluated study design, findings' consistency, evidence's directness, and effect estimates' precision. The assessment provided an overall confidence rating for each outcome, guiding the interpretation of results and conclusions. A summary of findings table was created using the GRADE Working Group's software GRADEpro GDT (**S2 Table**).

Results

The search strategy is provided in **S1 Table**. **Fig 1** illustrates the literature search process. Database searches identified 466 references; 314 articles were identified from all databases after removing duplicates. Of these, 282 were excluded based on the title and abstract and 20 based on the full text, resulting in 12 articles for inclusion (**Table 1**).

Table 1. Studies included for systematic review.

Author	Name
Aizawa et al., 2019 (91)	Bifidobacterium and lactobacillus counts in the gut microbiota of patients with bipolar disorder and healthy controls
Coello et al., 2019 (92)	Gut microbiota composition in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives
Flowers et al., 2017 (93)	Interaction between atypical antipsychotics and the gut microbiome in a bipolar disease cohort
Flowers et al., 2019 (94)	Effects of atypical antipsychotic treatment and resistant starch supplementation on gut microbiome composition in a cohort of patients with bipolar disorder or schizophrenia.
Gashaw et al., 2021 (95)	Assessment of gut bacteria profile and antibiotic resistance pattern among psychotropic drug users: comparative cross-sectional study
Hu et al., 2019 (96)	Gut microbiota changes in patients with bipolar depression
Ioannou et al., 2024 (97)	Reproducible gut microbial signatures in bipolar and schizophrenia spectrum disorders: a metagenome-wide study
Jiang et al., 2019 (98)	The microbiome in bipolar depression: a longitudinal study of one pair of monozygotic twins
Lai et al., 2022 (99)	Metagenomic analysis reveals gut bacterial signatures for diagnosis and treatment outcome prediction in bipolar depression
Lu et al., 2019 (100)	Gut microbiota in bipolar depression and its relationship to brain function: an advanced exploration.
Severance et al., 2013 (101)	Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia.
Xi et al., 2023 (102)	Brain-gut microbiota multimodal predictive model in patients with bipolar depression

Overview of study characteristics

Demographic and clinical characteristics of the study samples are presented in detail in **Table 2** and **3**. The study with the largest sample was conducted in Baltimore, U.S. (N = 294), and the remaining study samples ranged from N = 6 to N = 231. All studies were conducted between 2013 and 2024. Location varied widely between studies, including the U.S., China, Denmark, Ethiopia, Japan, and the Netherlands, and most patients were recruited from local psychiatric hospitals. In some studies, a variety of medication combinations was used, such as antidepressants and benzodiazepines, further complicating the results. Most studies (10/12) include HCs (**Table 2**). In two studies, BP patients were further divided into quetiapine-responded and non-responded patients based on whether the treatment reduced HAMD-17 score by 50% compared to baseline and a random forest classification model (99,102). Two studies also recruited unaffected relatives (UR) and BP patients (92,98). Three studies also included patients with schizophrenia spectrum disorder (SSD) (95,97,101).

Table 2. Demographic and clinical characteristics of included studies.

Study	Sample size*	Location	Design	Sample type	Diagnosis	Response	Medications (N)
Aizawa 2019 (91)	N = 122 HC = 58 (♀ 36; ♂ 22) BP = 39 (♀ 22; ♂ 17) AAP = 13 LL = 29	Tokyo, Japan	Cross-sectional observational cohort	Inpatient Community	BP = 39 BP-I = 13 BP-II = 26	N/A	***AAP:*** Sodium valproate (8), Carbamazepine (4) ***Antidepressant*** (12) ***Lithium*** (16) ***Lamotrigine*** (13)
Coello 2019 (92)	N = 229 HC = 77 (♀ 47; ♂ 30) UR = 39 (♀ 21; ♂ 18) BP = 113 (♀ 70; ♂ 43)	Copenhagen, Denmark	Cross-sectional observational cohort	Community	BP-I = 44 BP-II = 65 BP NOS = 4	N/A	***AAP*** (43) ***Antidepressants*** (30) ***Antiepileptics*** (58) ***Lithium*** (44)

	AAP = 43 LL = 44						
Flowers 2017 (93)	N = 117** AAP = 49 (♀ 34; ♂ 12) NAAP = 68 (♀ 48; ♂ 21) LL = 31	Michigan, U.S.	Cross-sectional observational cohort	Community	BP = 117	N/A	***AAP:*** Clozapine, Olanzapine, Risperidone, Quetiapine, Asenipine, Ziprasodone, Lurasidone, Aripiprazole, Paliperidone, Iloperidone. ***Antidepressants*** (52)***:*** Bupropion, Venlafaxine, Sertraline, Duloxetine, Fluoxetine, Citalopram, Escitalopram. ***Mood stabilizers*** (60)***:*** Topiramate, Phenobarbital, Lamotrigine, Gabapentin, Divalproex sodium, Carbamazepine, Lithium. ***Benzodiazepines*** (32): Lorazepam, Alprazolam, Temazepam, Clonazepam, Diazepam.
Flowers 2019 (94)	N = 37 AAP = 21 (♀ 9; ♂ 12) LL = 16 (♀ 7; ♂ 9)	Michigan, U.S.	Cross-sectional interventional longitudinal cohort	Community	*AAP group:* BP-I = 9 BP-II = 3 SZA = 5 SCZ = 4 *LL group:* BP-I = 10 BP-II = 6	N/A	***AAP*** (*3 weeks*)*:* Clozapine, Olanzapine, Risperidone, Quetiapine, Ziprasidone + Starch (*2 weeks*). ***Mood stabilizer*** (*3 weeks*)*:* Lithium, Lamotrigine ***Concomitant medications*****:** Antidepressants, Benzodiazepines, Medications for hypertension, diabetes mellitus, and hyperlipidemia.
Gashaw 2021 (95)	N = 214** HC = 107 (♀ 27; ♂ 80) SCZ = 57 BP = 28 Depression = 21	Jimma, Ethiopia	Cross-sectional observational cohort	Inpatient Community	SCZ = 57 BP = 28 Depression = 21	N/A	***Antipsychotics*** (54) ***Mood stabilizers*** (14) ***Antidepressants*** (11) ***Combination therapy*** (28)
Hu 2019 (96)	N = 97 HC = 45 (♀ 22; ♂ 23) BP = 52 (♀ 25; ♂ 27)	Zhejiang, China	Cross-sectional interventional longitudinal cohort	Inpatient Community	BP-I = 12 BP-II = 38 BP NOS = 2	N/A	***Quetiapine*** (4 weeks) Maintenance dose: 200-300mg/day
Ioannou 2024 (97)	N = 231 HC = 128 (♀ 77; ♂ 51) BP = 66 (♀ 48; ♂ 18) AAP = 34 LL = 35 NAAP = 35 SSD = 37 (♀ 16; ♂ 21) AAP = 28 LL = 3	Groningen, Netherlands	Cross-sectional observational cohort	Inpatient Community	BP = 66 SCZ/SZA = 37	N/A	***Antipsychotics*** (62) ***Lithium*** (38) ***Antidepressants*** (29) ***Anticonvulsants*** (23)

	NAAP = 1 5						
Jiang 2019 (98)	N = 6 HC = 4 (♀ 2; ♂ 2) UR = 1 (♀ 1) BP = 1 (♀ 1)	Zhejiang, China	Longitudinal case-control	Inpatient Community	BP = 1	N/A	***Lamotrigine*** Maintenance dose: 100mg/day ***Quetiapine*** Maintenance dose: 50mg/day
Lai 2022 (99)	N = 122 HC = 60 (♀ 31; ♂ 29) BP = 62 (♀ 23; ♂ 39)	Zhejiang, China	Cross-sectional interventional longitudinal cohort	Inpatient Community	BP-I = 12 BP-II = 45 BP NOS = 5	NBP = 19*** RBP = 35 Other = 9	***Quetiapine*** (4 weeks) Initial dose: 50mg/day Maintenance dose: 200-300mg/day
Lu 2019 (100)	N = 63 HC = 27 (♀ 12; ♂ 15) BP = 36 (♀ 15; ♂ 21)	Zhejiang, China	Cross-sectional interventional longitudinal cohort RCT	Inpatient Community	BP-I = 10 BP-II = 26	N/A	***Quetiapine*** (4 weeks) Initial dose: 50mg/day Maintenance dose: 300mg/day ***Propranolol***: 10-20mg ***Glycerine enema***
Severance 2013 (101)	N = 294 HC = 78 (♀ 56; ♂ 22) BP = 75 (♀ 52; ♂ 23) AAP = 57 NAAP = 18 SCZ = 141 (♀ 56; ♂ 85)	Baltimore, U.S. Cologne, Germany	Cross-sectional observational cohort	N/A	BP = 75 SCZ = 141	N/A	***Antipsychotics*** SCZ = 141 BP = 57
Xi 2023 (102)	N = 142 HC = 39 (♀ 23; ♂ 16) BP = 103 QTP = 75 (♀ 38; ♂ 37)	Zhejiang, China	Cross-sectional interventional longitudinal cohort	Inpatient Community	BP = 103	RBP = 43*** NBP = 32	***Quetiapine*** (4 weeks) Maintenance dose: 200-300mg/day

AAP, atypical antipsychotics.
BP, bipolar disorder.
HC, healthy controls.
LL, lithium- or lamotrigine-treated group.
NAPP, No atypical antipsychotics.
NBP, quetiapine non-responded patients.
NOS, not otherwise specified.
QTP, quetiapine.
RBP, quetiapine responded patients.
RCT, registered clinical trial.
SCZ, schizophrenia.
SSD, schizophrenia spectrum disorders.
SZA, schizoaffective disorder.
UR, unaffected first-degree relative.
*Participants included in the final data analysis.
**There was inconsistency in the total number of participants reported and the breakdown of participants by sex.
***Based on the degree of improvement in depressive severity post-treatment (HAMD change ≥ 50%), patients were classified into responder and non-responder groups.

Study design

Most studies employed a cross-sectional cohort design. There was significant heterogeneity between studies; among the 12 articles, one was a registered clinical trial (100) and six were longitudinal studies (94,96,98–100,102); thus only a subset shared comparability. Three studies specified a priori taxa for study, as opposed to studying the entire gut microbiota (95,100,101). Four

studies (4/12) were interventional, where participants underwent a 3-4 week treatment with psychotropic medications (94,99,100,102). These studies employed a fixed dose of quetiapine (300mg/day) without a discernible dose-response correlation. The remaining eight studies were observational, where researchers monitored and compared the effects of psychotropic medications between individuals who were taking psychotropics and those who did not.

Potential confounds when studying the microbiome, including age, sex, BMI, and medications, were all recorded. BP patients were recruited and diagnosed using various means, including admission in the hospital's inpatient/outpatient unit, using DSM-IV or DSM-V, Young Mania Rating Scale (YMRS), Hamilton Anxiety Rating Scale (HAMA), Hamilton Depression Rating Scale (HDRS), Montgomery-Asberg Depression Rating Scale (MADRS), Mini International Neuropsychiatric Interview (MINI), Diagnostic Interview for Genetic Studies (DIGS). Most studies excluded patients with substance abuse, cognitive impairments, intellectual disabilities, pregnancy, severe physical disabilities, and uses of antibiotics, probiotics, and/or prebiotics within 4 weeks of screening. A variety of sequencing methods (metagenomic sequencing, 16s RNA sequencing, qPCR) and analysis pipelines (PERMOVA, AMOVA, LEfSe, PCoA) were used to characterize microbiome composition (**Table 3**).

Table 3. Study criteria and analysis methodology of included studies.

Study	**Study criteria**		**Analysis methods**		
	Inclusion criteria*	**Exclusion criteria***	**Analysis types**	**BP Diagnosis**	**Covariates**
Aizawa 2019 (91)	Diagnosed BP from the outpatient clinic of the National Center of Neurology and Psychiatry	Prior medical history of central nervous system disease, including epilepsy and severe head injury, substance abuse or dependence, mental retardation, recent use of antibiotics, history of gastrointestinal surgery, severe congenital abnormalities, or any severe medical conditions.	16s or 23S rRNA targeted RT-qPCR Radioimmunoassay ANCOVA	MINI DSM-IV YMRS HAMD-17	Age Sex BMI Age of onset Comorbidities Education Medication
Coello 2019 (92)	Newly diagnosed or first episode BP from the Copenhagen Affective Disorder Clinic	N/A	16s rRNA sequencing Immunoturbidimetric assay PERMANOVA	DSM-V SCAN ICD-10 HAMD-17 YMRS IPAQ	Age Sex Smoking Waist circumference Physical activity Medication Illness duration
Flowers 2017 (93)	Diagnosed BP from the Prechter Longitudinal Study of Bipolar Disorder	N/A	16s rRNA sequencing AMOVA Inverse Simpson Diversity Index LEfSe LDA	DIGS HDRS YMRS ASRM PHQ-9	Age Sex BMI Medication
Flowers 2019	BP-I, BP-II, or BP NOS	Unable to give informed consent	16s rRNA sequencing	DSM-IV	Age

(94)	BP with Psychosis SCZ or SZA BP treated with an AAP—clozapine, olanzapine, risperidone, quetiapine, or ziprasidone—or lithium and/or lamotrigine for at least 6 months	Hospitalization or antimicrobial exposure within 6 months; receipt of systemic corticosteroids, immunosuppressant drugs, cytotoxic agents, or hormonal contraceptives; presence of any serious medical condition that would significantly affect weight changes; uncontrolled gastrointestinal disorders; chronic heavy alcohol consumption; or recent unstable dietary history	PERMANOVA PERMDISP LEfSe ASA24 SF-36		Sex Race Education BMI Nutrition Hospitalization Metabolic syndrome Physical activity Smoking Medication
Gashaw 2021	Psychiatry patients from Jimma Medical Centre psychiatric clinic	Antibiotics use within the last 6 months of the data collection.	Antimicrobial susceptibility testing	N/A	Age Sex Socio-demographic Medication Illness duration
Hu 2019 (96)	Diagnosed BP with a current depressive episode from Psychiatric Department of First Affiliated Hospital HDRS-17 score ≥14 First episode or psychotropic drug free for at least 3 months	Comorbid psychiatric disorders Severe physical diseases Acute/chronic infections Substance abuse Pregnancy Breast feeding Antibiotics, probiotics, or prebiotics use for less than 4 weeks before study	16s rRNA sequencing PERMOVA LEfSe PCoA PCR	DSMM-IV-TR HDRS-17 MADRS YMRS MINI	Age Sex BMI Age of onset Duration of illness Illness duration Medication
Ioannou 2024 (97)	BP and SSD patients from the Department of Psychiatry of the University Medical Center Groningen	Pregnancy or breastfeeding Active liver-, kidney- or pancreatic disease, other clinically significant or unstable medical problem, including inflammatory bowel disorder (IBP), short bowel syndrome or acute/ chronic pancreatitis.	Metagenomic shotgun sequencing PCoA PERMOVA OLS	DSM MINI	Age Sex BMI Diet BPRS Smoking Education Income Medication
Jiang 2019 (98)	Hospitalized BP	N/A	16s rRNA sequencing LEfSe PCoA	HDRS	Age Sex BMI Educational Physical activity Diet Alcohol consumption Smoking Antibiotics Medication
Lai 2022 (99)	Diagnosed BP HDRS-24 ≥ 14 Drug-naïve Psychotropic substances-free for at least 3 months MADRS ≤ 2	Chronic infection, severe systemic diseases, autoimmune diseases. Antibiotic, prebiotics, probiotics within 4 weeks before screening. Pregnancy, lactation, menstruation females.	Metagenomic sequencing rs-fMRI PERMANOVA LEfSe	DSM-IV-TR YMRS HAMA HDRS-24 MADRS MINI	Age Sex BMI Education Age of onset Illness duration

	Absence of apparent suicide thoughts or past attempted suicide	Comorbid psychiatric disorders History of cranial trauma. Contraindications for MRI			Socio-demographic
Lu 2019 (100)	Diagnosed BP from inpatient/outpatient department of the First Affiliated Hospital No treatments or medications stopped for more than 3 months	Gastrointestinal disease, infectious disease, fever, other physical diseases Autoimmune disease, endocrine disease, other mental disorders Antibiotics, probiotics, prebiotics, synbiotics, or yoghurt within a month Taking lactulose, prokinetic drugs, or antibiotics treatment in the last month History of substance abuse (nicotine dependence, caffeine use, and others).	MADRS YMRS NIRS measurement T lymphocyte flow cytometry qPCR	SCID DSM-IV-TR MADRS YMRS MINI	Age Sex Marriage BMI Education Age of onset Illness duration
Severance 2013 (101)	Diagnosed BP and SCZ Age 18-65 years old	Substance abuse/dependence Mental retardation or medical disorders affecting cognitive performance	ELISA (sCD14, LBP)	DSM-IV	Age Sex BMI Race Smoking
Xi 2023 (102)	Diagnosed BP depressed from Psychiatric Department of First Affiliated Hospital HAMD-17 ≥ 14 First episode or free from psychotropics for at least 3 months No probiotic preparation for at least 1 month No history of respiratory, urinary, or digestive infections	Psychiatric comorbidities and cognitive impairments Serious suicidal ideation or behavior, or intense euphoria, substance abuse (alcohol, narcotics, etc.) Severe physical sickness, intestinal disease Pregnancy or breastfeeding women	Metagenomic sequencing rs-fMRI PCoA	DSM-IV-TR HAMD-17 YMRS MINI	Age Sex BMI Smoking Handedness HAMD

ASA24, Automated Self-Administered 24-Hour Dietary Assessment Tool.
ASRM, Altman Self-Rating Mania Scale.
BPRS, Brief Psychiatric Rating Scale.
BP, bipolar disorder.
DIGS, Diagnostic Interview for Genetic Studies.
ELISA, Enzyme-linked Immunosorbent Assay.
HAMA, Hamilton Anxiety Rating Scale.
HDRS-24, 24-item Hamilton Depression Rating Scale.
IPAQ, International Physical Activity Questionnaire.
LDA, Linear Discriminant Analysis.
LEfSe, Linear Effect Size Analysis.
MADRS, Montgomery-Asberg Depression Rating Scale.
MINI, Mini International Neuropsychiatric Interview/
MRI, Magnetic Resonance Imaging.
NIRS, Near-infrared Spectroscopy.
OLS, Ordinary Least Squares Linear Regression.
PCoA, Principal Coordinates Analysis
PERMDISP, Permutational Multivariate Analysis of Dispersion.
PERMOVA, Permutational Analysis of Variance.
PHQ-9, Patient Health Questionnaire-9.
qPCR, Quantitative Polymerase Chain Reaction.
rs-fMRI, Resting-state Magnetic Resonance Imaging.
SCAN, Schedules for Clinical Assessment in Neuropsychiatry.
SCID, Structured Clinical Interview for DSM-IV-TR disorders.
SCZ, Schizophrenia.

SF-36, 36-Item Short-Form Health Survey.
SSD, Schizophrenia Spectrum Disorder.
YMRS, Young Mania Rating Scale.
*for BP/SCZ patients.

Quality assessment results

The quality assessment results are reported in **Fig 2** and **S2 Table**. ROBINS-I V2 tool was used to evaluate the risk of bias for all included studies, which examines seven bias domains: confounding, intervention classification, participant selection, deviations from intended interventions, missing data, outcome measurement, and result reporting. There was author overlap between papers, with the same groups having published most papers (i.e., Flowers et al. (93,94) and Hu et al. (96,99,100,102)), which might create overlap between study populations. We did not exclude these studies as we considered that the risk of bias would be negligible. Most studies acknowledged their limitations due to the lack of control for confounding factors, such as diet and lifestyle (**Fig 2**). We also assessed the certainty of evidence using the GRADE approach for any reported correlation between psychotropic use and changes in gut microbial species (**S2 Table**) (103). Evidence is categorized by high, moderate, low and very low certainty.

Effects of mood stabilizers on gut microbiome in bipolar disorder

Our collected research studies yield mixed results. In two studies, based on the degree of improvement in depression severity post-treatment (quetiapine) compared to baseline (HAMD-17/HDRS-124 change ≥ 50%), patients were classified into responder and non-responder groups, with the responders' scores significantly lower than non-responders (99,102). Interestingly, before quetiapine treatment, non-responders had significantly lower gut microbial alpha diversity than responders, with *Eubacterium biforme*, *Weissella confusa*, *Oribacterium sinus*, and *Barnesiella intestinihominis* being more abundant in responders and *Clostridium bartlettii*, *Bacteroides_sp_2_1_22*, and *Bacteroides_sp_3_1_19* more in non-responders (102).

There were generally no significant associations between alpha or beta diversity and psychotropic treatment (91,94,97,100,102). However, in two studies, Lai et al., 2022 (99) found increased alpha diversity in BP patients after a 4-week treatment of atypical antipsychotics (AAPs), and the Flowers research group noticed a significantly decreased alpha diversity in treated female patients that was not observed in males (93,94). In a longitudinal monozygotic twin study, microbiome abundance was also at the lowest level following a female patient's hospitalization and treatments of lamotrigine, lithium, and quetiapine (98). This sex-dependent change is consistent with preclinical studies of AAPs-treated rat models like olanzapine and risperidone, where weight gain

and microbial composition changes only occurred in females (104–106). Olanzapine was shown to convert gut microbial composition into an obesogenic profile (78) and risperidone seemed to decrease “lean gut microbiota” (107). Children and adolescents under chronic risperidone treatment also showed an upregulation of metabolic pathways linked with weight gain (108). These findings reinforce that AAPs alter the inflammatory milieu and metabolic profile of BP patients drastically, shifting them towards an obesogenic one.

The emergence of antimicrobial resistance among gut bacteria in patients treated with psychotropic medications was a notable concern. The most frequently isolated bacteria from BP patients and HC were *E. coli*, with antibiotic resistance patterns differing between the two groups (95). Amoxicillin clavulanic acid, cefuroxime, ceftriaxone, cefepime, cefotaxime, meropenem, ciprofloxacin, and tetracycline resistance were significantly higher among *E. coli* bacteria isolated from participants taking psychotropic drugs than *E. coli* bacteria isolated from apparently HC. This shows that multidrug-resistant bacteria and extended-spectrum beta-lactamase-producing (ESBL) strains are significantly more prevalent in BP patients taking psychotropics. The overall rate of multidrug resistance among bacteria isolated from patients taking psychotropics was 63%, whereas it accounts for 42.1% among bacteria isolated from HC. Furthermore, the odds of isolating ESBL-producing Enterobacteriaceae were notably higher in patients treated with antipsychotic drugs for over a year. This raises questions about the indirect effects of psychotropic medications on microbial ecology, possibly mediated by altered gut environments or medication-induced immune modulation (95).

While some studies reported changes only at the genus level, others also documented changes at the species level. When analyzing the changes by specific bacteria, we identified three groups, encompassing both genus and species: bacteria that increased in abundance after treatment, those that did not, and those with mixed results (**Table 4**).

Table 4. Changes in gut microbiome composition upon psychotropics treatment.

Increased abundance	**Decreased abundance**	**Mixed results**
Anaerococcus vaginalis (99)	*Akkermansia* (93)	*Bifidobacteria* (100)
Anaerofustis stercorihominis (99)	*Alistipes* (94,96)	*Bifidobacterium dentium* (99)
Anaeroglobus (96)	*Bacteroides_sp_2_1_22* (102)	*Clostridium bartlettii* (99,102)
Anaeromassilibacillus (97)	*Bacteroides_sp_3_1_19* (102)	*Ruminococcaceae* (98)
Barnesiella intestinihominis (102)	*Bilophila unclassified* (99)	*Ruminococcus obeum* (99)
Campylobacter hominis (99)	*Enterococcus hirae* (99)	
Clostridium perfringens (99)	*Faecalibacterium* (98)	
Clostridium scindens (99)	*Sutterella* (93)	
Collinsella (96)		
Enterobacter (98)		

Enterobacter cloacae (99) *Eubacterium biforme* (102) *Eubacterium rectale* (100) *Klebsiella* (96,97) *Klebsiella pneumoniae* (97) *Lachnospiraceae* (93) *Lactobacillus* (96) *Leuconostoc unclassified* (99) *Oribacterium sinus* (102) *Paraprevotella* (96) *Porphyromonas uenonis* (99) *Solobacterium* (96) *Streptococcus parasanguinis* (99) *Streptococcus salivarius* (99) *Streptococcus cristatus* (99) *Veillonella* (96) *Weissella confusa* (102)		

Increased bacteria abundance post-treatment

Increased abundance of 23 genera and 18 bacterial species were observed in BP patients treated with antipsychotics and lithium, and anticonvulsant and antidepressant use were not associated with any of the taxa (**Table 4**). These specific species include *Anaerococcus vaginalis, Anaerofustis stercorihominis, Barnesiella intestinihominis, Campylobacter hominis, Clostridium perfringens, Clostridium scindens, Enterobacter cloacae, Eubacterium biforme, Eubacterium rectale, Klebsiella pneumoniae, Leuconostoc unclassified, Oribacterium sinus, Porphyromonas uenonis, Ruminococcus obeum, Streptococcus parasanguinis, Streptococcus salivarius, Streptococcus cristatus, Weissella confusa.* These encompass a diverse range of species, including both Gram-positive and Gram-negative bacteria. Many Gram-positive species, such as *Lactobacillus*, are well-known for their roles in human microbiota, especially in the gut, and are involved in processes like fermentation, digestion, and the maintenance of gut health (109,110). *Eubacterium biforme*, *Eubacterium rectale*, and *Ruminococcus obeum* produce SCFAs like butyrate, maintaining gut barrier integrity and reducing inflammation . Their increased abundance could indicate adaptive microbial changes or therapeutic effects aimed at restoring gut homeostasis in treated patients. *Clostridium Cluster IV* is a butyrate-producing bacterium (117) and belongs to beneficial bacteria (100). However, some of these bacteria are pathogenic and can cause severe infection. *Clostridium perfringens* is an enteric pathogen that can produce various toxins and hydrolytic enzymes associated with intestinal diseases in humans and animals (99,118). Gram-negative bacteria like *Campylobacter hominis* and *Klebsiella pneumoniae* are also notable for their clinical significance; *Klebsiella*

pneumoniae are often opportunistic pathogens implicated in the urinary tract (119,120), while *Campylobacter hominis* is a known pathogen in gastrointestinal diseases (121,122).

In a longitudinal monozygotic twin study, KEGG pathway level 3 lipopolysaccharides (LPS) biosynthesis genes were over-represented in the gut following hospitalization and treatments of lamotrigine, lithium, and quetiapine (active state) (98). LPS are bacterial surface glycolipids produced by Gram-negative that can stimulate inflammation in the gut microbiome (123). During the remissive state, LPS biosynthesis genes are underrepresented compared to the active stage of BP, leading the patient's gut microbiome to become more similar to that of their monozygotic healthy twin. Throughout the responsive state (discharge and lithium withdrawal) and remissive (outpatient visit) BP state, *Ruminococcaceae* and *Faecalibacterium* abundance also increased significantly while *Enterobacter* declined (98). This is consistent with previous studies on the general effects of lithium on the gut microbiome (79,124). These results suggest that gut microbial function partially recovered after patients achieved full remission. Moreover, the overrepresented LPS biosynthesis genes may be related to the overgrowth of *Enterobacter* during the active stage, and patients' gut microbiome compositions corrected as they moved towards a healthy status (98).

Decreased bacteria abundance post-treatment

Following a 4-week quetiapine treatment, the abundance of *Akkermansia* (93), *Alistipes* (94,96), *Bacteroides_sp_2_1_22* (102), *Bacteroides_sp_3_1_19* (102), *Bilophila unclassified* (99), *Enterococcus hirae* (99), *Faecalibacterium* (98), *Ruminococcaceae* (98), *Sutterella* (93). *Alistipes* bacteria are within the *Bacteroidetes* phylum, enriched in untreated BP patients (96), and inversely associated with obesity and an animal-rich diet (125,126). *Akkermansia* was significantly decreased in non-obese patients treated with AAPs (93). This genus was previously inversely correlated with inflammation, insulin resistance, and lipid metabolism (127). Nevertheless, in two studies, no significant difference was found in bacterial counts before and after treatment (91,92).

Mixed findings

The abundance of *Clostridium bartlettii* varied across two studies (99,102) (**Table 4**). Both studies classified the BP patients as quetiapine responders and non-responders after a four-week treatment based on HAMD changes. Lai et al., 2022 identified an increased abundance of *Clostridium bartlettii* following quetiapine treatment in the study. This was accompanied by improvement in depressive symptoms following treatment, which appears to correlate with crucial emotion and behaviour recovery in BP patients but increased metabolic dysfunction (99).

Conversely, Xi et al. 2023, from the same research group, observed elevated *Clostridium bartlettii* levels in quetiapine non-responders, linking it to 5-HT deficiency and poorer remission outcomes (102). They argued that as that species has been linked to 5-HT deficiency (128), patients with excess *Clostridium bartlettii* may not do well in remission post-quetiapine treatment (102). They also added that *Clostridium bartlettii* had been associated with increased weight gain (99,129), with a decreased fecal abundance of *Clostridium bartlettii* following metformin treatment in three trials (130–132). These findings suggest that the species may have a complex role in quetiapine treatment responses, potentially influencing metabolic dysfunction, weight gain, and mood regulation. However, whether and how the species has detrimental or rescuing effects on BP symptoms is unclear. Psychotropics (particularly quetiapine) may partially improve mood symptoms through interactions with beneficial bacteria while increasing the risk of metabolic disturbance in more susceptible patients through interactions with other species of gut bacteria.

The findings for *Bifidobacteria* were also inconsistent. One study reported a significant increase in *Bifidobacteria* counts (100), whereas another found a decrease in *Bifidobacterium dentium* after quetiapine treatment (99) (**Table 4**). In a study conducted by Lu et al., after a four-week quetiapine treatment, the populations of both anaerobic *Bifidobacteria* and *Eubacterium rectale* proliferated compared to baseline, coinciding with a decline in the MADRS score and an increase in *Bifidobacteria-to-Enterobacteriaceae* (B/E) ratio (100). The authors suggested these bacteria could serve as biomarkers for therapeutic effects, but their lack of a placebo control leaves causality unclear (**Fig. 2**). Interestingly, in a separate study conducted by the same group, a four-week quetiapine treatment decreased the abundance *Bifidobacterium dentium*, implying its potential role in improved depressive symptoms post-treatment (99). Nevertheless, the absence of healthy controls in their fMRI analysis presents some biases and limits these associations (**Fig 2**).

The findings on the abundance of *Ruminococcus obeum* species and the family *Ruminococcaceae* following four weeks of quetiapine treatment present another conflict. While one study shows an increase in *Ruminococcus obeum* following quetiapine treatment (97), another identifies an ongoing increase in *Ruminococcaceae* during the responsive and remissive states of BD, despite initial decreases in the active state (98). This is particularly intriguing given that this same genus was enriched in the HC group. This warrant further investigation into the mechanistic pathways of the bacteria and their metabolites in BD progression and therapy.

Correlated functional imaging changes

Two studies from our search employed fMRI to investigate the correlation between gut bacterial species and neural activity (99,102). However, Lai et al., 2022 only collected fMRI results from untreated BP patients (99). In contrast, Xi et al., 2023 collected fMRI data from HC and all BP patients before and after they underwent a 4-week quetiapine treatment (102). They showed that the FC and grey matter volume (GMV) of quetiapine-responding BP patients were closer to those of HC than non-responders, suggesting that successful quetiapine treatment may restore some neural function and connectivity to a more normative state. Moreover, quetiapine-responding patients had lower intra-network FC within DMN and between the DMN and other networks (i.e., frontoparietal network and ventral attention). This lower FC was negatively correlated with *TM7_TM7b* (bacteria from the *Saccharibacteria* phylum), *Weissella confusa*, and positively correlated with *Clostridium bartlettii*. FC within the DMN is positively correlated with 5-HT signal transduction (133), which is related to the primary action of quetiapine (e.g., blocking dopamine D2 (134) and 5-HT_{2A} receptors (135,136), while activating 5-HT_{1A} (137)). Significantly higher DMN connections indicate that non-responders have dysfunctional or abnormal 5-HT signal transduction, making 5-HT more difficult for the quetiapine to bind to the 5-HT receptor (102) (**Fig 3**).

These imaging findings suggest that quetiapine non-responders may have additionally abnormal 5-HT signaling, leading to insufficient quetiapine binding at key receptors. This dysfunction within the 5-HT system contributes to the persistent DMN hyperconnectivity observed, amplifying an already maladaptive neural state.

Discussion

The gut-brain axis is a bidirectional communication system involving the CNS, enteric nervous system, and gut microbiota. The gut microbiome interacts with the brain via neurotransmitters, metabolites, and hormones (138). Thus, changes to the CNS in psychiatric disorders, such as neurotransmitter dysregulations, can affect the gastrointestinal microenvironment and vice versa (139). Studying the effects of medications on the gut microbiome in BP is essential for advancing our understanding of treatment mechanisms and improving patient outcomes. A significant number of individuals with BP do not respond adequately to existing medications such as mood stabilizers, antipsychotics, or antidepressants (140,141). Gut dysbiosis may perpetuate systemic inflammation or disrupt neurochemical signalling, such as serotonin and GABA pathways, contributing to poor treatment outcomes. By examining how medications influence gut bacteria, researchers can uncover underlying mechanisms of treatment resistance and identify new

personalized strategies to support patients who do not respond to conventional therapies. The gut microbiome is highly individualized and shaped by diet, lifestyle, genetics, and environment (142). Medications may impact each person's microbiome differently, contributing to variability in therapeutic outcomes. By studying these effects, researchers can develop microbiome-based biomarkers to predict how a patient will respond to specific treatments, enabling clinicians to tailor therapies to individual needs. This approach aligns with the growing emphasis on precision medicine in mental health care (143).

This review provides the most comprehensive analysis to date on the effects of BP treatments on the gut microbiome. We found that quetiapine and lithium were associated with an increased abundance of various gut bacteria species. Specifically, elevated levels of *Clostridium perfringens* and *Enterobacter cloacae*—opportunistic pathogens—suggest gut dysbiosis following treatment. On the other hand, the increased abundance *of Eubacterium biforme, Eubacterium rectale*, and *Ruminococcus obeum,* which produce beneficial SCFAs, indicates that quetiapine may have some positive effects on restoring gut homeostasis in treated patients. Additionally, the use of psychotropic drugs may contribute to antibiotic resistance, as observed in studies of *E. coli* from patients on these medications. This suggests that psychotropic drugs could promote the emergence of multidrug-resistant bacteria. Some studies also propose that gut microbiome composition could serve as a non-invasive biomarker for diagnosing and predicting treatment outcomes in mental health disorders like BP.

This review presents several limitations. We restricted the scope of this review to studies published in peer-reviewed journals, which introduces a potential for publication bias. Studies reporting significant or positive findings are more likely to be published, while those presenting null or negative results may remain unpublished. This bias could distort the conclusions regarding the effects of medications on the gut microbiome. Incorporating grey literature, such as conference proceedings or preprints, could mitigate this limitation by providing a more comprehensive and balanced representation of the available evidence. Such sources often include novel or preliminary findings, which are particularly valuable in rapidly evolving fields like microbiome research. Moreover, this review did not conduct any statistical analyses due to the substantial heterogeneity in the methodologies of the included studies. Variations in study design, populations, analytical techniques, and reporting standards precluded meaningful quantitative synthesis, further limiting the robustness of the conclusions.

The majority of included studies focus on the effects of specific medications like quetiapine and lithium, potentially neglecting other treatments used in BP, such as valproate. However, we include studies with negative findings (91). This limited scope might hinder the generalizability of

findings to all BP medications. Studies assessing the gut microbiome and BP treatments likely vary in methodologies, including participant demographics, dosage, treatment duration, and microbiome assessment techniques. This heterogeneity complicates direct comparisons and synthesis of results. Many studies on the gut microbiome are cross-sectional, providing a snapshot of microbiome composition at a single time point. These studies may fail to capture the dynamic changes in gut bacteria over the course of treatment, limiting insights into causality. Differences in microbiome sequencing technologies (e.g., 16S rRNA sequencing vs. shotgun metagenomics) and analytical pipelines could introduce variability in results, making it difficult to draw consistent conclusions. Many microbiome studies involve small cohorts, limiting statistical power and the ability to detect subtle or clinically meaningful changes in the gut microbiome. While the review discusses changes in microbiome composition, it lacks mechanistic insights and may not provide sufficient mechanistic understanding of how these changes interact with psychiatric treatments and contribute to treatment resistance or efficacy. While the review highlights immediate changes in gut bacteria associated with treatments, it may not sufficiently address long-term impacts, such as the potential development of antibiotic resistance or chronic dysbiosis.

Gaps in current research

Potential sources of bias in these studies encompass variations in sample characteristics, notably the marked clinical heterogeneity within the BP cohort, geographical and dietary influences, and potential author overlap between papers (i.e., Flowers et al., – same groups have published most papers). As a result, it is challenging to interpret the disparities in measures of diversity and abundance between studies. Only four studies were interventional, where participants underwent a 3-4 week treatment with psychotropic medications (94,99,100,102). These studies employed a fixed dose of quetiapine (300mg/day) without a discernible dose-response correlation. The remaining eight studies were observational, where researchers monitored and compared the effects of psychotropic medications between individuals who were taking psychotropics and those who did not. There was significant heterogeneity between studies. Out of the total number of studies conducted (12 in total), only a subset shared comparability due to their utilization of a cross-sectional cohort design for comparing individuals with BP to HC groups. These studies generally featured modest sample sizes; in some studies, the patient group did not receive placebo treatment as a control (100).

Geographical variation may present another confounder since regional diets can vary greatly. While antibiotics, probiotics, and prebiotics were prohibited in many studies, it is essential to note that participants did not adhere to a standardized diet or physical activity, both pivotal environmental

factors influencing gut microbiota composition (193). Some studies also allowed for a combination of medications in addition to quetiapine treatment, so underlying polypharmacy precludes us from drawing definitive conclusions. It would be difficult to control for this in future studies since most BP patients exist on an affective mood spectrum, which necessitates the use of multiple medications (144). Additionally, participant age was not matched between the patient and control groups and gut microbiome composition changes rapidly with age (145,146).

Only a subset of included studies was comparable; however, they often had small sample sizes, and in some cases, the patient group did not receive a placebo treatment as a control (100). None of the studies examined differences in AAP responses between BP-I and BP-II. Nevertheless, the findings may provide important preliminary information, as the study began at the time of diagnosis and continued with follow-up assessments throughout the treatment period. Some studies examined gut microbiota within the context of various psychiatric conditions, such as SCZ, alongside BP and explored diverse treatments, including starch and probiotics; however, the outcomes of these investigations fell beyond the scope of this review.

Another constraint pertained to the dropout rate among patients who initially received treatments, leading to the re-evaluation and final inclusion of only a subset of the patient population (96). Consequently, certain studies could not elucidate whether alterations in microbiota traits were tied to treatments. To establish a cause-and-effect relationship between BP gut microbiota and bipolar pharmacological treatments, a longitudinal cross-sectional cohort design is imperative. It is worth mentioning that the distinction between BP-I and BP-II in relation to gut microbiome composition changes following treatment was not examined in the studies.

Future directions

The intestinal microbiome may govern varying drug responses between the sexes. An increasing number of microbiome studies have revealed endocrine bacteria that can produce and respond to hormones (e.g., 5-HT, DA, and estrogen) and regulate hormonal homeostasis by inhibiting gene transcription (e.g., prolactin) (147). Studies have also shown that females appear to have significantly higher levels of *Bifidobacteria* and *Bilophila* than males (148,149). This difference in baseline microbiome composition may explain why females under AAP treatment may express decreased gut microbiome species diversity (i.e., *Akkermansia muciniphila*) compared to HC, while males showed no difference (93). Some other studies have reported associations between the menstrual cycle and BP, particularly in a subgroup of females with enhanced hormonal sensitivity. This population seems to experience heterogeneous menstrual cycle effects on depressive,

hypomanic, and manic episodes (150), leading to greater chronobiological disruptions across the follicular and luteal phases (151). Sex-biased responses to psychotropics can also be due to inherent differences in physiology between sexes. Compared to females, on average, males have a higher dissolution rate, which is the rate-limiting step in drug absorption, as well as larger fluid volumes in the stomach and small intestine (following the normalization of body weight) (152). Females, on the other hand, have, on average, higher fasted state pH, lower acid secretion, smaller stomachs, and longer colonic transit time (153–155). These can all influence the ionization and solubility of pH-sensitive drugs, thereby affecting absorption and drug bioavailability (156,157). Notably, pre-menopausal females have a significantly longer gastric emptying time while post-menopausal females have a shorter time, which is more similar to average males (158).

As discussed previously and shown in the studies, many AAPs and antidepressants exhibit bactericidal and bacteriostatic activity and induce gut microbial antibiotic resistance (159–161). Although some antibiotics have been suggested as conjunctive therapies for BP, including tetracyclines (162), such as minocycline (163–165) and doxycycline (166–168), dangers from the global spread of antibiotic resistance should be considered. Plus, persistent use of psychotropics may also harm commensal beneficial gut bacteria. Accordingly, more caution should be made when prescribing psychotropics, which perhaps can be tapered off with alternative treatments such as cognitive behavioural therapies, education, and support groups (169,170).

It has not yet been possible to establish a healthy gut composition in individuals with BP, which can be defined by a balanced and diverse microbiome, strong intestinal integrity, and efficient digestive function; thus the interindividual gastrointestinal microbiome variations further complicate effective interventions (171,172). Dietary interventions may help enhance responses to drug therapy (173,174) and address metabolic side effects caused by the medications (75,78). Antioxidants and vitamin B supplements have been considered as adjuncts to antipsychotic drugs for SCZ patients (175), and high fibre intakes are correlated with reduced risk of depressive symptoms (176,177). Furthermore, compared to non-vegetarians, vegetarians typically have a more rapid gastrointestinal transit time and gastric emptying (178). One of the most widely studied dietary interventions is the Mediterranean Diet, characterized by a high level of fibre, polyunsaturated fatty acids, anti-inflammatory and antioxidative products (179). These can increase *Faecalibacterium* strains (linked to butyrate metabolism), diminishing gut inflammation (180), reducing *Firmicutes* and *Proteobacteria phyla* (181), and stimulating fermentation in the lumen and adsorption of bile acid (178); therefore, this diet leads to better drug adsorption and bioavailability (81). Administering purified prebiotic Bimuno™ galacto-oligosaccharides powder with olanzapine can increase *Bifidobacterium* and attenuated weight gain induced by the AAP (75). Similarly, administering

olanzapine with an antibiotic containing neomycin, metronidazole, and polymyxin B can attenuate weight gain and metabolic problems in rats (77).

Pro- and prebiotics have been used to reduce inflammation, decrease cardiovascular disease risks, and promote weight loss (182,183). They have also exhibited anxiolytic and antidepressant effects. In fact, a study of 80 first-episode drug-naive BP patients who underwent psychotropic therapy supplemented with probiotics showed clinical symptom improvements and reduced oxidative stress markers (allantoic acid, choline, creatine, hypoxanthine, inosine, uric acid) 3-month post-intervention (184). In another research report, probiotic supplementation improved attention, psychomotor processing speed, and executive functions also in 20 euthymic BP patients after 3 months (185).

Another innovative approach targeting gut microbiota in BP is faecal microbiota transplantation (FMT). This method involves transferring stool from a healthy donor into the pathological colon to restore a healthy gut microbiome and ameliorate systems (186). Studies on these in the psychiatry field are still limited (187). One significant success was reported in a case study where a BP patient, 6 months after undergoing FMT from their spouse, showed neither manic nor depressive symptoms (188). This method also entails some complicated challenges regarding donors and recipients' compatibility as well as sources (189).

Lastly, there are some immune-based therapeutic strategies suggested for BP and MDD patients which do not follow the conventional treatment approach (190). For instance, celecoxib is a nonsteroidal anti-inflammatory drug commonly used to treat arthritis and joint pain but has been shown to be highly effective for bipolar depression in minimizing anxiety and facilitating treatment response (191). The same results were obtained with aspirin (192). N-acetylcysteine (NAC), a medication usually used to treat acetaminophen poisoning, was also proven to mitigate gut dysbiosis in mice (193) and improve depressive symptoms in BP patients (190,194).

Conclusion

Medications such as antidepressants, antipsychotics, and anticholinergics significantly influence microbial physiology, altering the intestinal microbiome in ways that can impact therapeutic efficacy. These effects are particularly important to consider when developing drugs for neurological disorders, as microbial metabolism can either enhance or diminish treatment outcomes. Research on the psychotropic effects of medications on the gut microbiome in BP has produced mixed results, likely due to factors such as the anatomy and physiology of the gastrointestinal tract, the release and absorption profiles of the medications, polypharmacy, and the limitations of current

study designs. Our systematic review of 12 studies highlights that psychotropic treatments, including lithium and quetiapine, promote the growth of beneficial gut bacteria associated with intestinal health but also increase the abundance of pathogenic bacteria linked to metabolic dysfunctions. These changes are more pronounced in female patients, who demonstrate greater microbial diversity shifts following treatment. Additionally, psychotropic treatments are associated with an increase in multidrug antibiotic resistance within the gut microbiome, raising concerns about potential long-term health risks.

Quetiapine responders—patients with improved depressive symptoms—exhibited distinct gut microbiome profiles that were more similar to those of healthy individuals compared to non-responders. This group also demonstrated neural connectivity patterns akin to healthy subjects, suggesting a possible gut-brain axis interaction contributing to treatment efficacy. Conversely, non-responders may possess inherent gut dysbiosis that compromises treatment outcomes. The role of *Clostridium bartlettii* in BP remains unclear, with mixed findings on its abundance following quetiapine treatment. These findings underscore the dual impact of psychotropic medications on gut microbiota, highlighting both potential therapeutic benefits and risks. The increased prevalence of beneficial bacteria alongside pathogenic and antibiotic-resistant strains reflects the complexity of microbial responses to treatment. While the mechanisms driving these shifts and their causal relationships remain uncertain, this analysis offers promising directions for improving treatment outcomes in BP. Leveraging insights into gut microbiome dynamics could lead to more personalized and effective therapies, reducing side effects and addressing the diverse needs of BP patients.

Author statements

Author contributions

Truong An Bui: Conceptualization, Formal analysis, Validation, Data curation, Visualization Writing; Benjamin R. O'Croinin: Formal analysis, Validation, Data Curation, Writing – Review and Editing; Liz Dennett: Methodology, Software, Writing – Review and Editing; Ian R. Winship: Writing – Review and Editing, Supervision; Andrew Greenshaw: Conceptualization, Writing – Review and Editing, Supervision.

Availability of data

The data supporting the findings of this study are available within the article and its supplementary materials.

Competing interests

The authors have no competing interests to declare. This study received no financial support from any funding agency in the public, commercial, or not-for-profit sectors.

References

1. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008 Feb;134(2):577–94.
2. Schmidt C, Stallmach A. Etiology and pathogenesis of inflammatory bowel disease. Minerva Gastroenterol Dietol. 2005 Jun;51(2):127–45.
3. Lukiw WJ. Gastrointestinal (GI) Tract Microbiome-Derived Neurotoxins—Potent Neuro-Inflammatory Signals From the GI Tract via the Systemic Circulation Into the Brain. Front Cell Infect Microbiol. 2020 Feb 12;10:22.
4. King CH, Desai H, Sylvetsky AC, LoTempio J, Ayanyan S, Carrie J, et al. Baseline human gut microbiota profile in healthy people and standard reporting template. PLOS ONE. 2019 Sep 11;14(9):e0206484.
5. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al. Diversity of the human intestinal microbial flora. Science. 2005 Jun 10;308(5728):1635–8.
6. Davenport ER, Mizrahi-Man O, Michelini K, Barreiro LB, Ober C, Gilad Y. Seasonal variation in human gut microbiome composition. PloS One. 2014;9(3):e90731.
7. Smith SM, Vale WW. The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues Clin Neurosci. 2006 Dec;8(4):383–95.
8. Sheng JA, Bales NJ, Myers SA, Bautista AI, Roueinfar M, Hale TM, et al. The Hypothalamic-Pituitary-Adrenal Axis: Development, Programming Actions of Hormones, and Maternal-Fetal Interactions. Front Behav Neurosci [Internet]. 2021 [cited 2023 Jul 3];14. Available from: https://www.frontiersin.org/articles/10.3389/fnbeh.2020.601939
9. Strandwitz P. Neurotransmitter modulation by the gut microbiota. Brain Res. 2018 Aug 15;1693(Pt B):128–33.
10. Chen Y, Xu J, Chen Y. Regulation of Neurotransmitters by the Gut Microbiota and Effects on Cognition in Neurological Disorders. Nutrients. 2021 Jun 19;13(6):2099.
11. Bhatia NY, Jalgaonkar MP, Hargude AB, Sherje AP, Oza MJ, Doshi GM. Gut-Brain Axis and Neurological Disorders-How Microbiomes Affect our Mental Health. CNS Neurol Disord Drug Targets. 2023;22(7):1008–30.
12. Park AJ, Collins J, Blennerhassett PA, Ghia JE, Verdu EF, Bercik P, et al. Altered colonic function and microbiota profile in a mouse model of chronic depression. Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc. 2013 Sep;25(9):733-e575.
13. Tillmann S, Abildgaard A, Winther G, Wegener G. Altered fecal microbiota composition in the Flinders sensitive line rat model of depression. Psychopharmacology (Berl). 2019 May;236(5):1445–57.
14. Jiang H, Ling Z, Zhang Y, Mao H, Ma Z, Yin Y, et al. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav Immun. 2015 Aug;48:186–94.
15. Evans SJ, Bassis CM, Hein R, Assari S, Flowers SA, Kelly MB, et al. The gut microbiome composition associates with bipolar disorder and illness severity. J Psychiatr Res. 2017 Apr;87:23–9.
16. Schwarz E, Maukonen J, Hyytiäinen T, Kieseppä T, Orešič M, Sabunciyan S, et al. Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response. Schizophr Res. 2018 Feb;192:398–403.
17. Liu YZ, Wang YX, Jiang CL. Inflammation: The Common Pathway of Stress-Related Diseases. Front Hum Neurosci. 2017 Jun 20;11:316.
18. Chrobak A.A., Nowakowski J., Dudek D. Interactions between the gut microbiome and the central nervous system and their role in schizophrenia, bipolar disorder and depression. Arch

Psychiatry Psychother. 2016;18(2):5–11.
19. Hemmings SMJ, Malan-Müller S, van den Heuvel LL, Demmitt BA, Stanislawski MA, Smith DG, et al. The Microbiome in Posttraumatic Stress Disorder and Trauma-Exposed Controls: An Exploratory Study. Psychosom Med. 2017 Oct;79(8):936–46.
20. Painold A, Mörkl S, Kashofer K, Halwachs B, Dalkner N, Bengesser S, et al. A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode. Bipolar Disord. 2019 Feb;21(1):40–9.
21. Liu L, Wang H, Chen X, Zhang Y, Zhang H, Xie P. Gut microbiota and its metabolites in depression: from pathogenesis to treatment. EBioMedicine. 2023 Apr;90:104527.
22. Nikolova VL, Smith MRB, Hall LJ, Cleare AJ, Stone JM, Young AH. Perturbations in Gut Microbiota Composition in Psychiatric Disorders: A Review and Meta-analysis. JAMA Psychiatry. 2021 Dec 1;78(12):1343–54.
23. Afroz KF, Manchia M. Gut microbiome and psychiatric disorders. BMC Psychiatry. 2023 Jul 7;23(1):488.
24. Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. Lancet Psychiatry. 2016 Feb;3(2):171–8.
25. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, et al. Prevalence and Correlates of Bipolar Spectrum Disorder in the World Mental Health Survey Initiative. Arch Gen Psychiatry. 2011 Mar;68(3):241–51.
26. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Lond Engl. 2020 Oct 17;396(10258):1204–22.
27. Oldis M, Murray G, Macneil CA, Hasty MK, Daglas R, Berk M, et al. Trajectory and predictors of quality of life in first episode psychotic mania. J Affect Disord. 2016 May;195:148–55.
28. Gardner HH, Kleinman NL, Brook RA, Rajagopalan K, Brizee TJ, Smeeding JE. The economic impact of bipolar disorder in an employed population from an employer perspective. J Clin Psychiatry. 2006 Aug;67(8):1209–18.
29. Macneil CA, Hasty MK, Berk M, Henry L, Evans M, Redlich C, et al. Psychological needs of adolescents in the early phase of bipolar disorder: implications for early intervention. Early Interv Psychiatry. 2011 May;5(2):100–7.
30. Marwaha S, Durrani A, Singh S. Employment outcomes in people with bipolar disorder: a systematic review. Acta Psychiatr Scand. 2013 Sep;128(3):179–93.
31. Preuss UW, Schaefer M, Born C, Grunze H. Bipolar Disorder and Comorbid Use of Illicit Substances. Medicina (Mex). 2021 Nov 17;57(11):1256.
32. Vieta E, Berk M, Schulze TG, Carvalho AF, Suppes T, Calabrese JR, et al. Bipolar disorders. Nat Rev Dis Primer. 2018 Mar 8;4(1):1–16.
33. Smith DJ, Whitham EA, Ghaemi SN. Chapter 15 - Bipolar disorder. In: Aminoff MJ, Boller F, Swaab DF, editors. Handbook of Clinical Neurology [Internet]. Elsevier; 2012 [cited 2023 Jul 2]. p. 251–63. (Neurobiology of Psychiatric Disorders; vol. 106). Available from: https://www.sciencedirect.com/science/article/pii/B9780444520029000152
34. DSM Library [Internet]. [cited 2023 Mar 3]. Diagnostic and Statistical Manual of Mental Disorders. Available from: https://dsm.psychiatryonline.org/doi/book/10.1176/appi.books.9780890425787
35. American Psychiatric Assocation. Bipolar and Related Disorders. In: Diagnostic and Statistical Manual of Mental Disorders, Text Revision (DSM-5-TR). 5e ed.
36. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018 Mar;20(2):97–170.
37. Butler M, Urosevic S, Desai P, Sponheim SR, Popp J, Nelson VA, et al. Treatment for

Bipolar Disorder in Adults: A Systematic Review [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 [cited 2023 Mar 12]. (AHRQ Comparative Effectiveness Reviews). Available from: http://www.ncbi.nlm.nih.gov/books/NBK532183/
38. Joshi A, Bow A, Agius M. Pharmacological Therapies in Bipolar Disorder: a Review of Current Treatment Options. Psychiatr Danub. 2019 Sep 1;31(Suppl 3):595–603.
39. Butler M, Urosevic S, Desai P, Sponheim SR, Popp J, Nelson VA, et al. Drug Treatments for Acute Mania. In: Treatment for Bipolar Disorder in Adults: A Systematic Review [Internet] [Internet]. Agency for Healthcare Research and Quality (US); 2018 [cited 2023 Jul 2]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532191/
40. Cosgrove VE, Kelsoe JR, Suppes T. Toward a Valid Animal Model of Bipolar Disorder: How the Research Domain Criteria Help Bridge the Clinical-Basic Science Divide. Biol Psychiatry. 2016 Jan 1;79(1):62–70.
41. Scolnick EM. The Path to New Therapies for Schizophrenia and Bipolar Illness. FASEB J Off Publ Fed Am Soc Exp Biol. 2017 Apr;31(4):1254–9.
42. Kim Y, Santos R, Gage FH, Marchetto MC. Molecular Mechanisms of Bipolar Disorder: Progress Made and Future Challenges. Front Cell Neurosci [Internet]. 2017 [cited 2023 Jul 2];11. Available from: https://www.frontiersin.org/articles/10.3389/fncel.2017.00030
43. Salvadore G, Quiroz JA, Machado-Vieira R, Henter ID, Manji HK, Jr CAZ. The Neurobiology of the Switch Process in Bipolar Disorder: A Review. J Clin Psychiatry. 2010 May 4;71(11):12633.
44. Amann B, Radua J, König B, Simhandl C. Relapse Rates and Risk Factors of Bipolar Disorder: Conclusions of a Naturalistic 4 Year Follow-up Study. Eur Psychiatry. 2015 Mar;30(S1):1–1.
45. Kessing LV, Andersen PK, Vinberg M. Risk of recurrence after a single manic or mixed episode – a systematic review and meta-analysis. Bipolar Disord. 2018;20(1):9–17.
46. Abi-Dargham A, Horga G. The search for imaging biomarkers in psychiatric disorders. Nat Med. 2016 Nov;22(11):1248–55.
47. Wang YX, Deng M. Medical imaging in new drug clinical development. J Thorac Dis. 2010 Dec;2(4):245–52.
48. Masdeu JC. Neuroimaging in Psychiatric Disorders. Neurother J Am Soc Exp Neurother. 2011 Jan;8(1):93–102.
49. Etkin A, Powell J, Savitz AJ. Opportunities for use of neuroimaging in de-risking drug development and improving clinical outcomes in psychiatry: an industry perspective. Neuropsychopharmacology. 2024 Nov;50(1):258–68.
50. Yatham LN, Liddle PF, Lam RW, Shiah IS, Lane C, Stoessl AJ, et al. PET study of the effects of valproate on dopamine D(2) receptors in neuroleptic- and mood-stabilizer-naive patients with nonpsychotic mania. Am J Psychiatry. 2002 Oct;159(10):1718–23.
51. Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry. 2000 Oct 15;48(8):813–29.
52. Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ, et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry. 1999 Nov 15;46(10):1375–87.
53. Ongür D, Lundy M, Greenhouse I, Shinn AK, Menon V, Cohen BM, et al. Default mode network abnormalities in bipolar disorder and schizophrenia. Psychiatry Res. 2010 Jul 30;183(1):59–68.
54. Phillips ML, Swartz HA. A critical appraisal of neuroimaging studies of bipolar disorder: toward a new conceptualization of underlying neural circuitry and a road map for future research. Am J Psychiatry. 2014 Aug;171(8):829–43.
55. Zovetti N, Rossetti MG, Perlini C, Maggioni E, Bontempi P, Bellani M, et al. Default mode network activity in bipolar disorder. Epidemiol Psychiatr Sci. 2020 Sep 8;29:e166.
56. Strakowski SM, Eliassen JC, Lamy M, Cerullo MA, Allendorfer JB, Madore M, et al. fMRI

brain activation in bipolar mania: Evidence for disruption of the ventrolateral prefrontal-amygdala emotional pathway. Biol Psychiatry. 2011 Feb 15;69(4):381–8.
57. Yoon S, Kim TD, Kim J, Lyoo IK. Altered functional activity in bipolar disorder: A comprehensive review from a large scale network perspective. Brain Behav. 2020 Nov 18;11(1):e01953.
58. Zhao L, Bo Q, Zhang Z, Li F, Zhou Y, Wang C. Disrupted default mode network connectivity in bipolar disorder: a resting-state fMRI study. BMC Psychiatry. 2024 Jun 7;24(1):428.
59. Young LT, Warsh JJ, Kish SJ, Shannak K, Hornykeiwicz O. Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder. Biol Psychiatry. 1994 Jan 15;35(2):121–7.
60. Young AH, Hughes JH, Ashton CH. Brain 5-HT function in bipolar affective disorder. Acta Neuropsychiatr. 2000 Sep;12(3):91–5.
61. Mahmood T, Silverstone T. Serotonin and bipolar disorder. J Affect Disord. 2001 Sep;66(1):1–11.
62. Li H, Wang P, Zhou Y, Zhao F, Gao X, Wu C, et al. Correlation between intestinal microbiotal imbalance and 5-HT metabolism, immune inflammation in chronic unpredictable mild stress male rats. Genes Brain Behav. 2022 Jul;21(6):e12806.
63. Kwon YH, Wang H, Denou E, Ghia JE, Rossi L, Fontes ME, et al. Modulation of Gut Microbiota Composition by Serotonin Signaling Influences Intestinal Immune Response and Susceptibility to Colitis. Cell Mol Gastroenterol Hepatol. 2019 Jan 1;7(4):709–28.
64. Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, et al. Indigenous Bacteria from the Gut Microbiota Regulate Host Serotonin Biosynthesis. Cell. 2015 Apr 9;161(2):264–76.
65. Rogers GB, Keating DJ, Young RL, Wong ML, Licinio J, Wesselingh S. From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. Mol Psychiatry. 2016 Jun;21(6):738–48.
66. Takahashi H, Yahata N, Koeda M, Takano A, Asai K, Suhara T, et al. Effects of dopaminergic and serotonergic manipulation on emotional processing: a pharmacological fMRI study. NeuroImage. 2005 Oct 1;27(4):991–1001.
67. Seo D, Patrick CJ, Kennealy PJ. Role of Serotonin and Dopamine System Interactions in the Neurobiology of Impulsive Aggression and its Comorbidity with other Clinical Disorders. Aggress Violent Behav. 2008 Oct;13(5):383–95.
68. Hori Y, Iwaoki H, Mimura K, Nagai Y, Higuchi M, Minamimoto T. Effects of a 5-HT4 receptor antagonist in the caudate nucleus on the performance of macaques in a delayed reward task. Sci Rep. 2024 Aug 23;14(1):19619.
69. Lin P, Li D, Shi Y, Li Q, Guo X, Dong K, et al. Dysbiosis of the Gut Microbiota and Kynurenine (Kyn) Pathway Activity as Potential Biomarkers in Patients with Major Depressive Disorder. Nutrients. 2023 Apr 3;15(7):1752.
70. Gao K, Mu C long, Farzi A, Zhu W yun. Tryptophan Metabolism: A Link Between the Gut Microbiota and Brain. Adv Nutr. 2020 May 1;11(3):709–23.
71. Więdłocha M, Marcinowicz P, Janoska-Jaździk M, Szulc A. Gut microbiota, kynurenine pathway and mental disorders – Review. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Mar 2;106:110145.
72. Buey B, Forcén A, Grasa L, Layunta E, Mesonero JE, Latorre E. Gut Microbiota-Derived Short-Chain Fatty Acids: Novel Regulators of Intestinal Serotonin Transporter. Life. 2023 Apr 26;13(5):1085.
73. De Vadder F, Kovatcheva-Datchary P, Goncalves D, Vinera J, Zitoun C, Duchampt A, et al. Microbiota-Generated Metabolites Promote Metabolic Benefits via Gut-Brain Neural Circuits. Cell. 2014 Jan 16;156(1):84–96.
74. Liu P, Peng G, Zhang N, Wang B, Luo B. Crosstalk Between the Gut Microbiota and the Brain: An Update on Neuroimaging Findings. Front Neurol. 2019 Aug 13;10:883.

75. Kao ACC, Spitzer S, Anthony DC, Lennox B, Burnet PWJ. Prebiotic attenuation of olanzapine-induced weight gain in rats: analysis of central and peripheral biomarkers and gut microbiota. Transl Psychiatry. 2018 Mar 15;8(1):66.
76. Bahr SM, Weidemann BJ, Castro AN, Walsh JW, deLeon O, Burnett CML, et al. Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure. EBioMedicine. 2015 Nov;2(11):1725–34.
77. Davey KJ, Cotter PD, O'Sullivan O, Crispie F, Dinan TG, Cryan JF, et al. Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat. Transl Psychiatry. 2013 Oct 1;3(10):e309.
78. Morgan AP, Crowley JJ, Nonneman RJ, Quackenbush CR, Miller CN, Ryan AK, et al. The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse. PloS One. 2014;9(12):e115225.
79. Cussotto S, Strain CR, Fouhy F, Strain RG, Peterson VL, Clarke G, et al. Differential effects of psychotropic drugs on microbiome composition and gastrointestinal function. Psychopharmacology (Berl). 2019 May;236(5):1671–85.
80. Torrent C, Amann B, Sánchez-Moreno J, Colom F, Reinares M, Comes M, et al. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand. 2008;118(1):4–18.
81. Falony G, Vandeputte D, Caenepeel C, Vieira-Silva S, Daryoush T, Vermeire S, et al. The human microbiome in health and disease: hype or hope. Acta Clin Belg. 2019 Apr;74(2):53–64.
82. Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623–8.
83. Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry Off J World Psychiatr Assoc WPA. 2016 Jun;15(2):166–74.
84. Vancampfort D, Vansteelandt K, Correll CU, Mitchell AJ, De Herdt A, Sienaert P, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry. 2013 Mar;170(3):265–74.
85. McGuinness AJ, Davis JA, Dawson SL, Loughman A, Collier F, O'Hely M, et al. A systematic review of gut microbiota composition in observational studies of major depressive disorder, bipolar disorder and schizophrenia. Mol Psychiatry. 2022 Apr;27(4):1920–35.
86. Ortega MA, Álvarez-Mon MA, García-Montero C, Fraile-Martínez Ó, Monserrat J, Martinez-Rozas L, et al. Microbiota–gut–brain axis mechanisms in the complex network of bipolar disorders: potential clinical implications and translational opportunities. Mol Psychiatry. 2023 Jan 27;1–29.
87. Sublette ME, Cheung S, Lieberman E, Hu S, Mann JJ, Uhlemann AC, et al. Bipolar disorder and the gut microbiome: A systematic review. Bipolar Disord. 2021 Sep;23(6):544–64.
88. Obi-Azuike C, Ebiai R, Gibson T, Hernandez A, Khan A, Anugwom G, et al. A systematic review on gut–brain axis aberrations in bipolar disorder and methods of balancing the gut microbiota. Brain Behav. 2023;13(6):e3037.
89. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009 Jul 21;6(7):e1000097.
90. Boutron I, Page MJ, Higgins JP, Altman DG, Lundh A, Hróbjartsson A, et al. Considering bias and conflicts of interest among the included studies. In: Cochrane Handbook for Systematic Reviews of Interventions [Internet]. John Wiley & Sons, Ltd; 2019 [cited 2024 Dec 29]. p. 177–204. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/9781119536604.ch7
91. Aizawa E., Tsuji H., Asahara T., Takahashi T., Teraishi T., Yoshida S., et al. Bifidobacterium and Lactobacillus counts in the gut microbiota of patients with bipolar disorder and healthy controls.

Front Psychiatry. 2019;10(JAN):730.
92. Coello K., Hansen T.H., Sorensen N., Munkholm K., Kessing L.V., Pedersen O., et al. Gut microbiota composition in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. Brain Behav Immun. 2019;75((Coello, Munkholm, Kessing, Vinberg) Copenhagen Affective Disorders Research Centre (CADIC), Psychiatric Center Copenhagen, Rigshospitalet, and Faculty of Health and Medical Sciences, University of Copenhagen, Denmark(Hansen, Pedersen) The Novo Nordisk Fo):112–8.
93. Flowers SA, Evans SJ, Ward KM, McInnis MG, Ellingrod VL. Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort. Pharmacotherapy. 2017;37(3):261–7.
94. Flowers SA, Baxter NT, Ward KM, Kraal AZ, McInnis MG, Schmidt TM, et al. Effects of Atypical Antipsychotic Treatment and Resistant Starch Supplementation on Gut Microbiome Composition in a Cohort of Patients with Bipolar Disorder or Schizophrenia. Pharmacotherapy. 2019;39(2):161–70.
95. Gashaw M., Marame Z.H., Abera M., Ali S. Assessment of gut bacteria profile and antibiotic resistance pattern among psychotropic drug users: Comparative cross-sectional study. Infect Drug Resist. 2021;14((Gashaw) School of Medical Laboratory Science, Jimma University, Jimma, Ethiopia(Marame) Ambo University Referral Hospital Microbiology Laboratory, Ambo University Referral Hospital, Ambo, Ethiopia(Abera) Department of Psychiatry, Jimma University, Jimma,):1875–81.
96. Hu S, Li A, Huang T, Lai J, Li J, Sublette ME, et al. Gut Microbiota Changes in Patients with Bipolar Depression. Adv Sci Weinh Baden-Wurtt Ger. 2019;6(14):1900752.
97. Ioannou M, Borkent J, Andreu-Sánchez S, Wu J, Fu J, Sommer IEC, et al. Reproducible gut microbial signatures in bipolar and schizophrenia spectrum disorders: A metagenome-wide study. Brain Behav Immun. 2024 Oct 1;121:165–75.
98. Jiang H.-Y., Xu L.-L., Zhang X., Zhang Z., Ruan B. The microbiome in bipolar depression: A longitudinal study of one pair of monozygotic twins. Bipolar Disord. 2019;21(1):93–7.
99. Lai J, Li A, Jiang J, Yuan X, Zhang P, Xi C, et al. Metagenomic analysis reveals gut bacterial signatures for diagnosis and treatment outcome prediction in bipolar depression. Psychiatry Res. 2022;307(qc4, 7911385):114326.
100. Lu Q, Lai J, Lu H, Ng C, Huang T, Zhang H, et al. Gut Microbiota in Bipolar Depression and Its Relationship to Brain Function: An Advanced Exploration. Front Psychiatry. 2019;10(101545006):784.
101. Severance EG, Gressitt KL, Stallings CR, Origoni AE, Khushalani S, Leweke FM, et al. Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia. Schizophr Res. 2013;148(1–3):130–7.
102. Xi C, Li A, Lai J, Huang X, Zhang P, Yan S, et al. Brain-gut microbiota multimodal predictive model in patients with bipolar depression. J Affect Disord. 2023;323(h3v, 7906073):140–52.
103. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence [Internet]. [cited 2025 Jan 17]. Available from: https://training.cochrane.org/handbook/current/chapter-14
104. Davey KJ, O’Mahony SM, Schellekens H, O’Sullivan O, Bienenstock J, Cotter PD, et al. Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology (Berl). 2012 May;221(1):155–69.
105. Aichhorn W, Marksteiner J, Walch T, Zernig G, Hinterhuber H, Stuppaeck C, et al. Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents. J Child Adolesc Psychopharmacol. 2007 Oct;17(5):665–74.
106. Haack S, Seeringer A, Thürmann PA, Becker T, Kirchheiner J. Sex-specific differences in

side effects of psychotropic drugs: genes or gender? Pharmacogenomics. 2009 Sep;10(9):1511–26.
107. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013 Sep 6;341(6150):1241214.
108. Bahr SM, Tyler BC, Wooldridge N, Butcher BD, Burns TL, Teesch LM, et al. Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. Transl Psychiatry. 2015 Oct 6;5(10):e652.
109. Dempsey E, Corr SC. Lactobacillus spp. for Gastrointestinal Health: Current and Future Perspectives. Front Immunol. 2022;13:840245.
110. Rastogi S, Singh A. Gut microbiome and human health: Exploring how the probiotic genus Lactobacillus modulate immune responses. Front Pharmacol. 2022;13:1042189.
111. Mukherjee A, Lordan C, Ross RP, Cotter PD. Gut microbes from the phylogenetically diverse genus Eubacterium and their various contributions to gut health. Gut Microbes. 12(1):1802866.
112. Louis P, Young P, Holtrop G, Flint HJ. Diversity of human colonic butyrate-producing bacteria revealed by analysis of the butyryl-CoA:acetate CoA-transferase gene. Environ Microbiol. 2010 Feb;12(2):304–14.
113. Walker AW, Ince J, Duncan SH, Webster LM, Holtrop G, Ze X, et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J. 2011 Feb;5(2):220–30.
114. Mathewson ND, Jenq R, Mathew AV, Koenigsknecht M, Hanash A, Toubai T, et al. Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat Immunol. 2016 May;17(5):505–13.
115. Bolte LA, Vila AV, Imhann F, Collij V, Gacesa R, Peters V, et al. Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome. Gut. 2021 Jul 1;70(7):1287–98.
116. Fernández J, Redondo-Blanco S, Gutiérrez-del-Río I, Miguélez EM, Villar CJ, Lombó F. Colon microbiota fermentation of dietary prebiotics towards short-chain fatty acids and their roles as anti-inflammatory and antitumour agents: A review. J Funct Foods. 2016 Aug 1;25:511–22.
117. Moens F, De Vuyst L. Inulin-type fructan degradation capacity of Clostridium cluster IV and XIVa butyrate-producing colon bacteria and their associated metabolic outcomes. Benef Microbes. 2017 May 30;8(3):473–90.
118. Kiu R, Hall LJ. An update on the human and animal enteric pathogen Clostridium perfringens. Emerg Microbes Infect. 2018 Aug 6;7(1):141.
119. Clegg S, Murphy CN. Epidemiology and Virulence of Klebsiella pneumoniae. Microbiol Spectr. 2016 Feb;4(1).
120. Wang G, Zhao G, Chao X, Xie L, Wang H. The Characteristic of Virulence, Biofilm and Antibiotic Resistance of Klebsiella pneumoniae. Int J Environ Res Public Health. 2020 Aug 28;17(17):6278.
121. Linscott AJ, Flamholtz RB, Shukla D, Song Y, Liu C, Finegold SM. Fatal septicemia due to Clostridium hathewayi and Campylobacter hominis. Anaerobe. 2005;11(1–2):97–8.
122. Man SM, Kaakoush NO, Leach ST, Nahidi L, Lu HK, Norman J, et al. Host attachment, invasion, and stimulation of proinflammatory cytokines by Campylobacter concisus and other non-Campylobacter jejuni Campylobacter species. J Infect Dis. 2010 Dec 15;202(12):1855–65.
123. Candelli M, Franza L, Pignataro G, Ojetti V, Covino M, Piccioni A, et al. Interaction between Lipopolysaccharide and Gut Microbiota in Inflammatory Bowel Diseases. Int J Mol Sci. 2021 Jun 10;22(12):6242.
124. Huang S, Hu S, Liu S, Tang B, Liu Y, Tang L, et al. Lithium carbonate alleviates colon inflammation through modulating gut microbiota and Treg cells in a GPR43-dependent manner. Pharmacol Res. 2022;175(phc, 8907422):105992.
125. Clarke SF, Murphy EF, O'Sullivan O, Ross RP, O'Toole PW, Shanahan F, et al. Targeting the microbiota to address diet-induced obesity: a time dependent challenge. PloS One.

2013;8(6):e65790.
126. Silva FM, Kramer CK, de Almeida JC, Steemburgo T, Gross JL, Azevedo MJ. Fiber intake and glycemic control in patients with type 2 diabetes mellitus: a systematic review with meta-analysis of randomized controlled trials. Nutr Rev. 2013 Dec;71(12):790–801.
127. Schneeberger M, Everard A, Gómez-Valadés AG, Matamoros S, Ramírez S, Delzenne NM, et al. Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice. Sci Rep. 2015 Nov 13;5:16643.
128. Roager HM, Licht TR. Microbial tryptophan catabolites in health and disease. Nat Commun. 2018 Aug 17;9(1):3294.
129. Danzeisen JL, Calvert AJ, Noll SL, McComb B, Sherwood JS, Logue CM, et al. Succession of the turkey gastrointestinal bacterial microbiome related to weight gain. PeerJ. 2013 Dec 23;1:e237.
130. Mueller NT, Differding MK, Zhang M, Maruthur NM, Juraschek SP, Miller ER, et al. Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial. Diabetes Care. 2021 Jul;44(7):1462–71.
131. Elbere I, Silamikelis I, Dindune II, Kalnina I, Ustinova M, Zaharenko L, et al. Baseline gut microbiome composition predicts metformin therapy short-term efficacy in newly diagnosed type 2 diabetes patients. PloS One. 2020;15(10):e0241338.
132. Rosario D, Benfeitas R, Bidkhori G, Zhang C, Uhlen M, Shoaie S, et al. Understanding the Representative Gut Microbiota Dysbiosis in Metformin-Treated Type 2 Diabetes Patients Using Genome-Scale Metabolic Modeling. Front Physiol. 2018;9:775.
133. Conio B, Martino M, Magioncalda P, Escelsior A, Inglese M, Amore M, et al. Opposite effects of dopamine and serotonin on resting-state networks: review and implications for psychiatric disorders. Mol Psychiatry. 2020 Jan;25(1):82–93.
134. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry. 2000 Jun;57(6):553–9.
135. Ramadan E, Basselin M, Rao JS, Chang L, Chen M, Ma K, et al. Lamotrigine blocks NMDA receptor-initiated arachidonic acid signalling in rat brain: Implications for its efficacy in bipolar disorder. Int J Neuropsychopharmacol. 2012 Aug;15(7):931–43.
136. Willner K, Vasan S, Abdijadid S. Atypical Antipsychotic Agents. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Aug 25]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK448156/
137. Grinchii D, Dremencov E. Mechanism of Action of Atypical Antipsychotic Drugs in Mood Disorders. Int J Mol Sci. 2020 Dec 15;21(24):9532.
138. Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases | Signal Transduction and Targeted Therapy [Internet]. [cited 2024 Dec 7]. Available from: https://www.nature.com/articles/s41392-024-01743-1
139. North CS, Hong BA, Alpers DH. Relationship of functional gastrointestinal disorders and psychiatric disorders: Implications for treatment. World J Gastroenterol WJG. 2007 Apr 14;13(14):2020–7.
140. Poon SH, Sim K, Baldessarini RJ. Pharmacological Approaches for Treatment-resistant Bipolar Disorder. Curr Neuropharmacol. 2015 Sep;13(5):592–604.
141. Tondo L, Vázquez GH, Baldessarini RJ. Options for pharmacological treatment of refractory bipolar depression. Curr Psychiatry Rep. 2014 Feb;16(2):431.
142. Conlon MA, Bird AR. The Impact of Diet and Lifestyle on Gut Microbiota and Human Health. Nutrients. 2014 Dec 24;7(1):17–44.
143. Haggarty SJ, Karmacharya R, Perlis RH. Advances toward precision medicine for bipolar disorder: mechanisms & molecules. Mol Psychiatry. 2021 Jan;26(1):168–85.

144. Angst J, Cassano G. The mood spectrum: improving the diagnosis of bipolar disorder. Bipolar Disord. 2005;7(s4):4–12.
145. Ghosh TS, Shanahan F, O'Toole PW. The gut microbiome as a modulator of healthy ageing. Nat Rev Gastroenterol Hepatol. 2022 Sep;19(9):565–84.
146. Meng C, Feng S, Hao Z, Dong C, Liu H. Changes in gut microbiota composition with age and correlations with gut inflammation in rats. PLoS ONE. 2022 Mar 15;17(3):e0265430.
147. Edwards M, Dai R, Ahmed SA. Our Environment Shapes Us: The Importance of Environment and Sex Differences in Regulation of Autoantibody Production. Front Immunol. 2018;9:478.
148. Cross TWL, Kasahara K, Rey FE. Sexual dimorphism of cardiometabolic dysfunction: Gut microbiome in the play? Mol Metab. 2018 Sep;15:70–81.
149. Haro C, Rangel-Zúñiga OA, Alcalá-Díaz JF, Gómez-Delgado F, Pérez-Martínez P, Delgado-Lista J, et al. Intestinal Microbiota Is Influenced by Gender and Body Mass Index. PloS One. 2016;11(5):e0154090.
150. Teatero ML, Mazmanian D, Sharma V. Effects of the menstrual cycle on bipolar disorder. Bipolar Disord. 2014 Feb;16(1):22–36.
151. El Dahr Y, de Azevedo Cardoso T, Syan SK, Caropreso L, Minuzzi L, Smith M, et al. Investigating biological rhythms disruptions across the menstrual cycle in women with comorbid bipolar disorder and premenstrual dysphoric disorder. Arch Womens Ment Health. 2022 Apr;25(2):345–53.
152. Soldin O, Mattison D. Sex Differences in Pharmacokinetics and Pharmacodynamics. Clin Pharmacokinet. 2009;48(3):143–57.
153. Phan J, Benhammou JN, Pisegna JR. Gastric Hypersecretory States: Investigation and Management. Curr Treat Options Gastroenterol. 2015 Dec;13(4):386–97.
154. Feldman M, Barnett C. Fasting gastric pH and its relationship to true hypochlorhydria in humans. Dig Dis Sci. 1991 Jul;36(7):866–9.
155. Rao SSC, Kuo B, McCallum RW, Chey WD, DiBaise JK, Hasler WL, et al. Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2009 May;7(5):537–44.
156. Lahner E, Virili C, Santaguida MG, Annibale B, Centanni M. Helicobacter pylori infection and drugs malabsorption. World J Gastroenterol. 2014 Aug 14;20(30):10331–7.
157. Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462–7.
158. Bennink R, Peeters M, Van den Maegdenbergh V, Geypens B, Rutgeerts P, De Roo M, et al. Comparison of total and compartmental gastric emptying and antral motility between healthy men and women. Eur J Nucl Med. 1998 Sep;25(9):1293–9.
159. Cederlund H, Mårdh PA. Antibacterial activities of non-antibiotic drugs. J Antimicrob Chemother. 1993 Sep;32(3):355–65.
160. Caldara M, Marmiroli N. Antimicrobial Properties of Antidepressants and Antipsychotics—Possibilities and Implications. Pharmaceuticals [Internet]. 2021 Sep [cited 2023 Oct 19];14(9). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470654/
161. Rukavishnikov G, Leonova L, Kasyanov E, Leonov V, Neznanov N, Mazo G. Antimicrobial activity of antidepressants on normal gut microbiota: Results of the in vitro study. Front Behav Neurosci. 2023 Mar 22;17:1132127.
162. Chaves Filho AJM, Mottin M, Soares MVR, Jucá PM, Andrade CH, Macedo DS. Tetracyclines, a promise for neuropsychiatric disorders: from adjunctive therapy to the discovery of new targets for rational drug design in psychiatry. Behav Pharmacol. 2021 Apr 1;32(2 & 3):123–41.
163. Murrough JW, Huryk KM, Mao X, Iacoviello B, Collins K, Nierenberg AA, et al. A pilot study of minocycline for the treatment of bipolar depression: Effects on cortical glutathione and oxidative stress in vivo. J Affect Disord. 2018 Apr 1;230:56–64.

164. Soczynska JK, Mansur RB, Brietzke E, Swardfager W, Kennedy SH, Woldeyohannes HO, et al. Novel therapeutic targets in depression: minocycline as a candidate treatment. Behav Brain Res. 2012 Dec 1;235(2):302–17.
165. Savitz JB, Teague TK, Misaki M, Macaluso M, Wurfel BE, Meyer M, et al. Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial. Transl Psychiatry. 2018 Jan 24;8(1):27.
166. Upmark F, Sjöqvist H, Hayes JF, Dalman C, Karlsson H. Doxycycline exposure during adolescence and future risk of non-affective psychosis and bipolar disorder: a total population cohort study. Transl Psychiatry. 2021 Sep 8;11(1):468.
167. Husain MI, Chaudhry IB, Khoso AB, Husain MO, Hodsoll J, Ansari MA, et al. Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial. Lancet Psychiatry. 2020 Jun;7(6):515–27.
168. Li XM, Shi ZM, Wang PJ, Hu H. Effects of ketamine in electroconvulsive therapy for major depressive disorder: meta-analysis of randomised controlled trials. Gen Psychiatry. 2020 Jun 16;33(3):e100117.
169. Papadimitriou GN, Dikeos DG, Soldatos CR, Calabrese JR. Non-pharmacological treatments in the management of rapid cycling bipolar disorder. J Affect Disord. 2007 Feb 1;98(1):1–10.
170. Geller B, Tillman R, Bolhofner K, Zimerman B. Pharmacological and non-drug treatment of child bipolar I disorder during prospective eight-year follow-up. Bipolar Disord. 2010;12(2):164–71.
171. Kerimi A, Kraut NU, da Encarnacao JA, Williamson G. The gut microbiome drives inter- and intra-individual differences in metabolism of bioactive small molecules. Sci Rep. 2020 Nov 11;10(1):19590.
172. Healey GR, Murphy R, Brough L, Butts CA, Coad J. Interindividual variability in gut microbiota and host response to dietary interventions. Nutr Rev. 2017 Dec 1;75(12):1059–80.
173. Firth J, Marx W, Dash S, Carney R, Teasdale SB, Solmi M, et al. The Effects of Dietary Improvement on Symptoms of Depression and Anxiety: A Meta-Analysis of Randomized Controlled Trials. Psychosom Med. 2019 Apr;81(3):265–80.
174. Jacka FN, O'Neil A, Opie R, Itsiopoulos C, Cotton S, Mohebbi M, et al. A randomised controlled trial of dietary improvement for adults with major depression (the 'SMILES' trial). BMC Med. 2017 Jan 30;15(1):23.
175. Eltokhi A, Janmaat IE, Genedi M, Haarman BCM, Sommer IEC. Dysregulation of synaptic pruning as a possible link between intestinal microbiota dysbiosis and neuropsychiatric disorders. J Neurosci Res. 2020 Jul;98(7):1335–69.
176. Kelly JR, Kennedy PJ, Cryan JF, Dinan TG, Clarke G, Hyland NP. Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front Cell Neurosci. 2015;9:392.
177. Bourassa MW, Alim I, Bultman SJ, Ratan RR. Butyrate, neuroepigenetics and the gut microbiome: Can a high fiber diet improve brain health? Neurosci Lett. 2016 Jun 20;625:56–63.
178. Deng J, Zhu X, Chen Z, Fan CH, Kwan HS, Wong CH, et al. A Review of Food–Drug Interactions on Oral Drug Absorption. Drugs. 2017 Nov 1;77(17):1833–55.
179. Widmer RJ, Flammer AJ, Lerman LO, Lerman A. The Mediterranean diet, its components, and cardiovascular disease. Am J Med. 2015 Mar;128(3):229–38.
180. Meslier V, Laiola M, Roager HM, De Filippis F, Roume H, Quinquis B, et al. Mediterranean diet intervention in overweight and obese subjects lowers plasma cholesterol and causes changes in the gut microbiome and metabolome independently of energy intake. Gut. 2020 Jul;69(7):1258–68.
181. Merra G, Noce A, Marrone G, Cintoni M, Tarsitano MG, Capacci A, et al. Influence of Mediterranean Diet on Human Gut Microbiota. Nutrients. 2020 Dec 22;13(1):7.
182. Slavin J. Fiber and prebiotics: mechanisms and health benefits. Nutrients. 2013 Apr 22;5(4):1417–35.
183. Kechagia M, Basoulis D, Konstantopoulou S, Dimitriadi D, Gyftopoulou K, Skarmoutsou N,

et al. Health benefits of probiotics: a review. ISRN Nutr. 2013;2013:481651.
184. Dickerson F, Adamos M, Katsafanas E, Khushalani S, Origoni A, Savage C, et al. Adjunctive probiotic microorganisms to prevent rehospitalization in patients with acute mania: A randomized controlled trial. Bipolar Disord. 2018 Nov;20(7):614–21.
185. Reininghaus E.Z., Wetzlmair L.-C., Fellendorf F.T., Platzer M., Queissner R., Birner A., et al. The impact of probiotic supplements on cognitive parameters in euthymic individuals with bipolar disorder: A pilot study. Neuropsychobiology. 2020;79(1):63–70.
186. Vindigni SM, Surawicz CM. Fecal Microbiota Transplantation. Gastroenterol Clin North Am. 2017 Mar;46(1):171–85.
187. Gupta S, Allen-Vercoe E, Petrof EO. Fecal microbiota transplantation: in perspective. Ther Adv Gastroenterol. 2016 Mar;9(2):229–39.
188. Hinton R. A case report looking at the effects of faecal microbiota transplantation in a patient with bipolar disorder. Aust N Z J Psychiatry. 2020;54(6):649–50.
189. Zhang P, Kong L, Huang H, Pan Y, Zhang D, Jiang J, et al. Gut Microbiota – A Potential Contributor in the Pathogenesis of Bipolar Disorder. Front Neurosci [Internet]. 2022 [cited 2023 Sep 21];16. Available from: https://www.frontiersin.org/articles/10.3389/fnins.2022.830748
190. Colpo GD, Leboyer M, Dantzer R, Trivedi MH, Teixeira AL. Immune-based strategies for mood disorders: facts and challenges. Expert Rev Neurother. 2018 Feb;18(2):139–52.
191. Halaris A, Cantos A, Johnson K, Hakimi M, Sinacore J. Modulation of the inflammatory response benefits treatment-resistant bipolar depression: A randomized clinical trial. J Affect Disord. 2020 Jan 15;261:145–52.
192. Rapoport SI. Aspirin and celecoxib may help to rectify a neurotransmission imbalance in bipolar disorder. Med Hypotheses. 2021 Apr;149:110536.
193. Zheng J, Yuan X, Zhang C, Jia P, Jiao S, Zhao X, et al. N-Acetylcysteine alleviates gut dysbiosis and glucose metabolic disorder in high-fat diet-fed mice. J Diabetes. 2019 Jan;11(1):32–45.
194. Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial. Biol Psychiatry. 2008 Sep 15;64(6):468–75.


Identification
Studies from databases/registers (n = 466)
PubMed (n = 174)
Embase (n = 133)
Scopus (n = 123)
MEDLINE (n = 25)
APA PsycInfo (n = 8)
References removed (n = 152)
Duplicates identified manually (n = 16)
Duplicates identified by Covidence (n = 78)
Marked as ineligible by automation tools (n = 58)
Screening
Studies screened (n = 314)
Studies excluded (n = 282)
Studies assessed for eligibility (n = 32)
Studies excluded (n = 20)
6 Abstract only (n = 6)
5 Wrong intervention (n = 5)
4 Protocol only (n = 4)
3 Wrong patient population (n = 3)
1 Wrong outcomes (n = 1)
1 Wrong study design (n = 1)
Included
Studies included in review (n = 12)
Included studies ongoing (n = 0)
Studies awaiting classification (n = 0)

covidence

Risk of bias domains

	D1	D2	D3	D4	D5	D6	D7	Overall
Aizawa et al., 2019 (59)	Some concerns	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Coello et al., 2019 (60)	Low risk	Low risk	Low risk	Some concerns	Some concerns	Low risk	Low risk	Some concerns
Flowers et al., 2017 (61)	Some concerns	Low risk	Low risk	Low risk	Some concerns	Low risk	Low risk	Some concerns
Flowers et al., 2019 (62)	Some concerns	Low risk	Low risk	Low risk	High risk	Low risk	Low risk	Some concerns
Gashaw et al., 2021 (63)	Low risk	Low risk	Low risk	Low risk	Some concerns	Low risk	Low risk	Low risk
Hu et al., 2019 (64)	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns	High risk	Low risk	High risk
Ioannou et al., 2024 (65)	Low risk	Low risk	Some concerns	Some concerns	Low risk	Low risk	Low risk	Some concerns
Jiang et al., 2019 (66)	Some concerns	High risk	Low risk	Low risk	Some concerns	Low risk	Low risk	High risk
Lai et al., 2022 (67)	Some concerns	Low risk	Low risk	Low risk	High risk	Low risk	Some concerns	Some concerns
Lu et al., 2019 (68)	Some concerns	Low risk	Low risk	Low risk	Low risk	Some concerns	Low risk	Some concerns
Severance et al., 2013 (69)	Some concerns	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Xi et al., 2023 (70)	Some concerns	Low risk	Low risk	Low risk	High risk	Low risk	Low risk	Some concerns

- Low risk of bias
- Some concerns of risk of bias
- High risk of bias
- ? No information

D1: Risk due to confounding
D2: Risk in classification of interventions
D3: Risk in selection of participants into the study
D4: Risk due to deviations from intended interventions
D5: Risk due to missing data
D6: Risk arising from measurement of the outcome
D7: Risk in selection of the reported result


Environmental signals
Diet
Bipolar medications
Antibiotics
Probiotics
Dietary fiber
Animal-derived saturated lipids
Dietary cholesterol
Starch
Gut microbiota
Signaling metabolites
LPS/endotoxin
Bile acids
SCFAs
Trimethylamine
Gut microbiota signaling metabolites allow communication with the brain
Lamina propria
Vagus nerve
Gut hormones
Microbial metabolites
Gut lumen
Neurochemical signaling
Dopamine pathways
Serotonin pathways
Noradrenalin pathways
GABA pathways